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Abstract 
 
Persistent infection with oncogenic human papillomaviruses (HPV), particularly 
HPV16, is associated with selective expression of two virally encoded proteins (E6 and 
E7). One action of HPV16.E7 protein is to subvert the innate immune system through the 
down-regulation of IFNγ pathways, modulation of antigen presentation, and suppression of 
Toll-like receptor 9 protein. 
K14.E7 transgenic mice, which express HPV16.E7 oncoprotein within basal 
keratinocytes under the control of the keratin 14 transcriptional promoter, have been 
extensively used as a model of HPV oncoprotein–induced immune suppression 
associated with human squamous cancers, in which only the E6 and E7 genes of the 
papillomavirus are expressed. It has previously been shown that skin grafts expressing 
HPV16.E7 oncoprotein are not spontaneously rejected when transplanted onto syngeneic 
animals, but they are rejected when certain components of the innate immune system are 
unavailable, confirming that the expression of HPV16.E7 in the epithelium results in the 
establishment of a local suppressive environment and the subversion of antigen-specific T 
cells. Therefore, successful strategies targeting HPV-associated cancer need to 
circumvent or disrupt the local suppressive environment. 
Topical immunotherapy with immunostimulatory agents has been used clinically to 
treat cancerous lesions including squamous cell and basal cell carcinoma in 
immunocompetent and immunosuppressed patients. Topical application of 2,4-
dinitrochlorobenzene (DNCB) is an effective therapy for condylomata acuminata caused 
by HPV infection. DNCB induced the complete clearance of HPV-associated warts in 
13/15 patients. However, the use of DNCB for treatment has been discouraged because of 
its mutagenic potential. The aim of my doctoral research is to understand the mechanism 
of DNCB-induced inflammation in K14.E7 transgenic mice which has been poorly 
understood. I hypothesized that understanding how induction of a vigorous acute 
inflammatory response by DNCB can break the local immune-suppressive environment 
and restore the effector function of adaptive immunity might lead to more acceptable 
treatments for persisting HPV infection. In support of this hypothesis, the present study 
showed that DNCB application along with E7 specific immunization therapy was capable 
of inducing HPV16.E7 skin graft rejection.  
Arginase, which metabolizes l-arginine to N-ornithine and urea, has been identified 
as a crucial regulator of inflammation. As inflammation decides the fate of HPV infection 
and arginase is an important regulator of inflammation and immunity, I investigated the 
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interaction between DNCB-induced inflammation and HPV16.E7 protein in the induction of 
arginase in K14.E7 transgenic mice. The first part of this study showed that topical DNCB 
application to skin expressing HPV16.E7 as a transgene induces a hyperinflammatory 
response, which is not seen in nontransgenic control animals. The E7-associated 
inflammatory response was characterized by enhanced expression of Th2 cytokines and 
increased infiltration of CD11b+Gr1intF4/80+Ly6ChiLy6Glow myeloid cells, producing 
arginase-1. Inhibition of arginase with an arginase-specific inhibitor, N(omega)-hydroxy-
nor-L-arginine, ameliorated the DNCB-induced inflammatory response.  
Furthermore, Th2 cytokines but not Th1 cytokines are induced in K14.E7 skin and 
these cytokines have been well-known as potent inducers of arginase-1 production in 
macrophages. In the second part of my study, I demonstrated that neutralization of these 
cytokines did not change the level of arginase activity in bone marrow-derived 
macrophages  cultured in DNCB treated K14.E7 skin explant supernatant, suggesting that 
IL-4 and IL-10 might not be necessary for the induction of arginase activity in DNCB 
treated K14.E7 skin. Interestingly, IL-17A, an important proinflammatory cytokine, was 
also induced in K14.E7 mice but not in wild-type nontransgenic mice and CD11b+F4/80+ 
but not lymphocytes are the major producer of IL-17A in DNCB treated K14.E7 skin. 
Importantly, IL-17A deficient K14.E7 mice express diminished arginase activity and 
develop an alleviated inflammatory response to DNCB. Furthermore, I demonstrated that 
the induction of arginase-1 is independent of adaptive immunity.  Thus, IL-17A produced 
by macrophage is responsible for enhanced arginase-1 expression in these cells.  
Taken together, my study suggests that HPV16.E7 protein enhances DNCB 
associated-production of IL-17A which mediates arginase-1 production by inflammatory 
monocytes (Macrophages) and consequent inflammatory cellular infiltration of the skin. 
Thus, these findings provide insights into the pro-inflammatory roles of IL-17A and 
arginase-1 axis in HPV16.E7 expressing skin in response to immunostimulation by DNCB, 
and imply a potential immune-based therapy strategy to break the tolerance to HPV 
persistent infection by modulating IL-17A/arginase-1 axis.  
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1.1 Human Papillomavirus-an oncogenic virus 
 
 1.1.1 HPV-associated cancers  
 
Human Papillomavirus (HPV) infection is an etiological factor for approximately 
5.2% of all types of cancer. Based on tissue distribution, HPVs are classified into two 
major genera: α and β genus (1). 
 The α-HPV genus, also referred to as mucosal HPV, can be detected mostly in the 
epithelium of the genital tract. HPVs in this genus are further grouped into low-risk and 
high-risk types dependent on their potential to cause cancer. Infection with low-risk types 
(such as HPV6, HPV11) results in genital warts, which are benign and unlikely to develop 
into cancer. In contrast, high-risk HPV types are responsible for the development of pre-
neoplastic and malignant lesions of the uterine cervix, anus, vulva, penis and orophary. 
Particularly, HPV16 and HPV18 account for 70% of cervical cancer cases worldwide (1). 
Furthermore, high-risk HPV types are also associated with head and neck squamous cell 
carcinoma (SCC) (2).  
The β-HPV genus (such as HPV5, HPV8), known as cutaneous HPV, causes 
common warts and  might lead to cutaneous SCC (3). It has been well documented that β-
HPV types (HPV 5 and 8) are associated with epidermodysplasia verruciformis, a rare 
autosomal recessive skin disorder (4). Furthermore, cutaneous HPV types might be 
cofactors in the early onset of cutaneous SCC. A recent study using a meta-analysis 
approach reported that cutaneous SCC were more likely to carry HPV than normal skin 
and higher prevalence of HPV was detected in keratinocyte tumors from 
immunosuppressed patients than those from immunocompetent patients (5). Nonetheless, 
the association of other HPV types and SCC remained debatable as HPVs are 
undetectable in SSC in some studies and further studies are required to dissect the role of 
HPV in skin cancers (6).  
 
 1.1.2 Exclusively intra-epithelial infectious cycle of HPV 
 
The genome of HPV is a circular double-stranded DNA molecule consisting of 
around 8,000 base pairs and up to ten (generally 8) open reading frames (ORFs). These 
ORFs in HPV16 encode two structural proteins (L1 and L2) and six nonstructural proteins 
(E1, E2 and E4-E7) (7). HPV particles enter undifferentiated stem cells in the basal layer 
of the stratified epithelium through microabrasion of the epithelium and establish stable 
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episomal genome in these cells. Briefly, HPV virions are unable to bind directly to basal 
cells rather they must first bind via their L1 capsid proteins to heparan sulfate 
proteoglycans on segments of the basement membrane after epithelial disruption. This 
process results in a conformation change, leading to exposure of L2 capsid N-treminus to 
furin cleavage site. Following L2 proteolysis, a previously unexposed surface of L1 binds 
to an unindentified secondary receptor on keratinocytes, facilitating endocytosis and the 
invasion of virions (8).  
Figure 1.1- HPV exclusively infects the epithelium. HPV life cycle begins with the 
infection of stem cells in the basal layer. Infected cells migrated vertically to suprabasal 
layers where virus genome amplification is initiated before the production of complete 
virions.  APC: antigen presenting cells. Adapted from (9).  
 
As the infected cells migrate to the proliferative suprabasal layer, viral early proteins 
are expressed to initiate viral DNA replication. At this stage, the expression of E6 and E7 
oncoproteins is tightly controlled and viral DNA replication is maintained at low level (50-
100 copies per cells) (Figure 1.1). When these cells reach the upper differentiated 
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compartment of the stratum spinosum and granulosum, the oncogenic HPVs have the 
ability to integrate their own genome into the human chromosome, resulting in a 
remarkable induction of E6 and E7 genes in carcinomas and many cases of high-grade 
squamous intraepithelial lesion (HSIL). Additionally, structural proteins (L1 and L2) are 
also produced to form the viral capsids which are packaged into mature infectious virions 
along with replicated genomes (1). 
 
1.1.3 HPV carcinogenesis 
 
Two nonstructural proteins (E6 and E7) from HPV types that are strongly 
associated with risk of cervical cancer (“high risk” HPVs including HPV16 and HPV18) are 
capable of interacting with a number of cellular proteins, particularly tumor suppressors 
including p53 and retinoblastoma protein (pRB) respectively, thereby inducing genomic 
instability, accumulation of oncogene mutations and loss of cell-growth control (10, 11). In 
addition, these nonstructural proteins are consistently expressed in premalignant cancer 
and strongly expressed in invasive cancer associated with high risk HPVs (12). Indeed, E6 
and E7 proteins have been shown to be involved not only in the regulation of viral 
replication and transcription, but also in the modulation of the host immune response to 
HPV infection (13). 
In summary, infection with high risk HPVs displays tropism towards squamous 
epithelium and results in overexpression of E6 and E7 oncoproteins that cause epidermal 
hyperplasia and carcinoma.  
 
1.2 Natural immune response to HPV infection and HPV-mediated 
immunosuppression 
 
1.2.1. Natural immune response to HPV infection 
 
The majority of HPV infections (80%) regress spontaneously, which is likely to be 
as a consequence of an effective immune response (Figure 1.2) (2). Regression of HPV-
induced lesions is strongly associated with the infiltration of virus specific T cells including 
CD4+ and CD8+ T cells, supporting a role for a cell-mediated immune response in lesion 
regression (15). CD8+ T cells are thought to produce Th1 cytokines, particularly IFNγ and 
exert cytolytic effects on target cells through MHC class I (MHCI) (16). Likewise, CD4+ T 
cells also secrete IFNγ but these cells can induce apoptosis via ligation of death receptors 
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with Fas or TRAIL (17). It has been reported that the cell-mediated immune response 
against HPV-derived proteins such as E2, E6 and E7 is of critical importance in the 
eradication of virus infection and lesion regression (18). The cell-mediated immunity is 
closely followed by humoral response in which B cells are stimulated by antigen presenting 
cells (APC) and CD4+ helper T cells to produce antibodies against major coat L1 protein 
(19). However, infected patients develop weak or no antibody responses to viral L2 protein 
and oncoproteins including E2, E6, E7 (20). 
In approximately 10% to 20% of infections, HPVs have skewed the host innate 
immune response towards chronic inflammation that facilitates their persistent infection 
and eventually invasive cancer (2). Accumulating evidence suggests that the 
establishment of HPV persistent infection and eventually invasive cancer is associated 
with virus-induced immunosuppressive mechanisms. The immunosuppressive 
mechanisms of HPV impact on different stages of innate and adaptive immunity including 
cytokine production, cross-presentation of antigens and antibody response (21).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2- The progression of HPV associated cervical cancer. Approximately 80% of 
HPV infections regress spontaneously by effective immune responses. 10%-20% of HPV 
infections progress to persistent infection and ultimately become invasive cancers. 
Adapted from (14).  
 
1.2.2 Modulation of epithelial innate immunity by HPV 
 
HPV infection and replication is restricted to the squamous epithelial tissues which 
cover the cavities and surfaces of the body including skin, gut, lung and genital tracts, and 
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which function as immune barriers against pathogens (1). The skin is subdivided into two 
distinct compartments, the epidermis and dermis. The epidermis is comprised of 95% 
keratinocytes (KCs) which act as sentinels of innate immunity through their ability to detect 
pathogens, secrete cytokines or become non-professional antigen presenting cells (9, 18).   
HPV has developed several strategies to evade the immune defenses. Firstly, as 
the virus life circle is strictly dependent on the differentiation program of epithelial cells, it is 
rare to detect HPV in other tissues other than squamous epithelial cells (1). This helps 
minimise the exposure of HPV antigens to the host immune system. Further, the virus 
does not cause cell death or inflammation during DNA replication, virion assembly and 
release process. Moreover, the expression of HPV E7 oncoprotein is restricted to the 
nucleus of keratinocytes where it is inaccessible for APC. In addition, the expression of 
viral late proteins (L1 and L2) is maintained at moderate levels and restricted to 
the differentiated superficial cell layers which are programmed to undergo apoptosis, 
thereby evading immune surveillance (2, 21).  
Furthermore, HPVs can dampen the generation of anti-viral cytokines by KCs. KCs 
express Toll-like receptors (TLRs) which can detect the presence of pathogens via the 
recognition of pathogen-associated molecular patterns (PAMPs). The recognition of viral 
infection is followed by the release of numerous proinflammatory cytokines that are 
required for the elimination of pathogens. HPV-16 E6 and E7 oncoproteins have been 
shown to inhibit the expression of TLR9 which is an important TLR sensing dsDNA virus 
infection (22). As a result, the majority of HPV infection is silent and inaccessible for 
immune recognition.  
Activation of TLR signaling in KCs results in type I IFN induction which is crucial for 
antiviral responses. The E6 and E7 oncoproteins of high risk HPV types have delayed the 
initiation of immune response in KCs by directly blunting the transcription of IFNα and 
IFNβ (23). Additionally, HPV16 and HPV18 E7 proteins have been shown to interfere with 
IFN-mediated signaling pathways through its ability to bind to interferon regulatory factor-1 
(IRF1), thereby reducing the transcription of IRF1 target genes such as monocyte 
chemoattractant protein-1 (MCP-1) and  transporter associated with  antigen processing 
protein-1 (TAP1) (24, 25).  
Tumor necrosis factor (TNF) is an activator of nuclear factor kappaB (NFκB) which 
is involved in the prohibition of cell proliferation, differentiation and induction of apoptosis. 
It has been shown that TNF exerts its anti-proliferative effect on HPV-16-immortalized 
keratinocytes through induction of NF-κB. However, several studies have reported that E6 
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and E7 proteins down-regulate the expression of TNF and NFκB,  thereby protecting HPV 
from the pro-inflammatory effect of these molecules (21).  
 
 1.2.3 Modulation of antigen presentation in APC 
 
In immune-competent individuals, viral antigens are processed and cross-presented 
to T cells by innate immune cells including macrophages, dendritic cells (DCs), and 
Langerhand cells (LCs) (18).  
DCs have the ability to link the innate and adaptive immune responses by 
presenting viral antigen to T cells in the lymphoid peripheral organs. It has been shown 
that the activation of the cell-mediated immune response is essential for the eradication of 
HPV infection (18). However, by unknown mechanisms HPV can induce the loss of LCs 
which are the principal DC population residing in the skin (26). Furthermore, data from 
patients and HPV transgenic mice have revealed that E7 loaded DCs fail to undergo 
maturation and immature DCs are tolerogenic rather than immunogenic to E7 specific T 
cells in draining lymph nodes (27). Additionally, E5 protein is responsible for the loss of 
MHC class I and transporter associated with antigen processing proteins (TAP) in HPV-
related cancers (28). Thus, these mechanisms enable HPVs to evade the surveillance of 
the innate immune system and establish a persistent infection. 
 
1.2.4 Modulation of T helper cell- derived cytokine production by HPV 
 
CD4+ T-helper cells set the cytokine milieu, determining the direction of the immune 
response to pathogens. Data from patients with intraepithelial and invasive cancer showed 
that T-helper cytokine network is deregulated during the carcinogenesis of cervical cancer 
(29). Infection with papillomavirus can shift the differentiation of T-helper cell towards Th2 
and T-regulatory cell phenotypes and reduce Th1 phenotype, leading to suppression of 
cellular immunity and progression to cancer (29).  Th1 cytokines including IL-2, TNFα and 
IFNγ were reduced in HPV-associated lesions as compared to healthy women. 
Conversely, these patients displayed increased level of IL-4 which is a signature of Th2 
cells (30, 31).  
Regulatory T cells (Treg) are a CD4+ T cell subset that express CD4, CD25 and 
transcription factor FOXP3 and mediate peripheral tolerance. Treg cells produce IL-10 
which can hinder cross-presentation by DCs, thereby preventing from an effective immune 
response to malignant cells. This cytokine has been shown to be associated with cervical 
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cancer progression. HPV E2, E6 and E7 proteins were shown to bind directly to the IL-10 
regulatory region to active gene transcription (36).  
Th17 cells are a distinct subset of T cells which are manifested by the production IL-
17A. It has been reported that IL-17A induced by Listeria-based immune therapy promotes 
the regression of tumor in HPV transplantatable mouse model (32).  In addition, the low 
concentration of transforming growth factor beta (TGF-β) and high level of IL-6 in the local 
inflammatory milieu are capable of activating Th17 cells to eliminate viral infection at 
mucosal surfaces (33). Nonetheless, in the context of cervical cancer, HPV E6 and E7 
proteins induce a high level of TGF-β, which might shift differentiation of naïve T cells into 
regulatory T cells (Tregs) instead of Th17 cells, which generate the local immuno-
suppression resulting in persistent infection (2, 34). In contrast, a recent study using 
HPV16 E7 trangenic skin transplantation has shown that IL-17A produced by CD4+ T cells 
is responsible for the suppression of immune effector functions (35).  
In conclusion, the innate immune response to HPV infection plays a crucial role in 
limiting viral infection during the early phase of infection and in shaping adaptive immunity. 
Nonetheless, high risk HPVs are able to subvert the recognition of innate immune cells as 
well as modulate the expression of T cell-derived cytokines through the action of their 
oncoproteins, thereby leading to their persistent infection and tumorigenesis.  
 
1.3 Models of HPV pathogenesis 
 
HPV E6 and E7 oncoproteins play crucial roles in cell transformation as well as 
immune-suppression. Therefore, development of a model that can simulate the complex 
viral oncoprotein-host immunity interactions might be useful for study of the 
immunosuppressive mechanisms driven by HPV and antiviral interventions.  
 
 1.3.1 In-vitro model 
 
It had been impossible to reproduce the HPV life cycle in-vitro since the virus is 
tissue tropic and its life cycle is tightly associated with the differentiation program of host 
keratinocytes. Recent studies have revealed that HPV-infected keratinocytes represent 
suitable and reliable tools to understand the interactions between viral proteins and cellular 
proteins as well as the epithelial immune response to the virus. There are two different 
approaches to generate HPV-infected keratinocytes: 1) immortalized cell lines derived 
from in-vivo lesions infected with HPV; 2) transfection of low-passage human keratinocytes 
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with full or partial HPV genomes. Subsequently, these immotalized cells will produce viral 
particles under differentiating conditions (37).  
Although HPV infected epithelial cells have been used as a tool to understand viral 
life cycle and the consequence of viral oncoproteins on cytokine production by 
keratinocytes, this model is labour intensive and time-consuming. Furthermore, the yield of 
immortalised clones after viral genome transfection is vey low even under optimal 
conditions (37).  
 
 1.3.2 In-vivo models 
 
 PV mouse model 
 
Naturally Papillomavirus (PV) infected animals including rabbits, cattle and rats 
have been employed as models to study HPV pathogenesis. However, these models are 
not favourably used in laboratory studies due to the size of animals as well as the lack of 
available reagents for validation. Thus, a recent mouse model (musPV) based on mice 
naturally infected with PVs has been developed. These mice develop papillomas and are 
able to transmit PV to others immune-compentent mice. This model has been used to 
elucidate the mechanism of PV latency and role of the immune system. However, findings 
from this model might not be relevant to human diseases caused by HPV due to the 
marked differences between musPV and HPV (38), and the need for immune suppression 
to allow infection with musPV.  
 
 Xenograft models 
 
Buitrago-Perez et al. developed a humanized model in which human skin 
transfected with plasmids carrying the HPV5 or HPV16 E7 gene was subsequently 
transplanted onto nu/nu immunodeficient mice. These mice displayed similar 
histopathological and molecular features as observed in HPV-associated lesions. 
Therefore, this model is proposed for studies of molecular mechanisms underlying HPV 
pathogenesis as well as pre-clinal validation of therapies for HPV-associated cancer (39). 
Although this model is able to recapitulate physiological conditions in a human context, it 
lacks a proper immunity and might not be useful to address anti-tumor therapies based on 
immune system interactions.  
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 Tumor transplantable model 
The tumor transplantable model is generated by subcutaneously injecting immune-
competent mice with TC-1 cells, which are primary mouse lung epithelial cells co-
transfected with HPV16 E6 and E7 and an activated ras oncogene (40). This model does 
not consider the properties of a naturally slow-growing tumor in which the antigen 
expression is maintained at a low level to evade the immune surveillance. Studies using 
this model to test the pre-clincal benefit of therapies have revealed that regression of  a 
tumor is mediated by E7 specific CD8+ T cells (16). Nonetheless, therapeutic approaches 
proposed by these studies that have showed promising results in this model, have mostly 
failed at clinical phase (13). This could be explained by the fact that fast growing tumor 
cells in this model might have different biological features from the slow-growing in-situ 
tumors.  
 
 HPV transgenic mouse  
K14.HPV16.E6/E7 mice which express HPV type 16 E6 or E7 oncoproteins within 
basal keratinocytes under the control of the keratin 14 transcriptional promoter, show 
epithelial hyperplasia (41-43). The Frazer group has previously shown that skin grafts 
expressing HPV16.E6/E7 oncoprotein are not spontaneously rejected when transplanted 
onto syngeneic animals, but are rejected when certain components of the innate immune 
system are unavailable, confirming that expression of E6 or E7 oncoprotein in the 
epithelium results in the establishment of a local suppressive environment and the 
subversion of antigen specific CD8+ T cells. By using this model, Mattarollo et al. revealed 
that invariant natural killer T cells (iNKTs) cell depletion causes K14.E7 skin graft rejection, 
suggesting that NKT cells infiltrating the skin are involved in the establishment of a local 
immune suppression environment in hyperplastic skin (44). 
When compared with the tumor transplantation model, the K14.E7 transgenic model 
better mimics the immunobiology of the chronic infection with HPV and of precancerous 
lesions caused by HPV (45). Although HPV specific antigen immunisation is sufficient to 
eradicate tumors in murine transplantable models, this immunotherapy strategy is 
ineffective in patients with HPV-associated cancer (46) and in the skin graft model. Thus, 
the K14.E7 model has been extensively used as model of HPV-associated squamous 
cancer to investigate the immunosuppressive mechanisms mediated by HPV (47). 
K14.E6/E7 transgenic mice might serve as an in-vivo model to study the interaction 
between the immune response and high-risk HPV oncoproteins. The in-depth 
Chapter 1 
 
 11 
understanding of immunosuppressive mechanisms driven by HPV oncoproteins might lead 
to the development of effective immunotherapies to reverse these mechanisms.  
 
 1.4 Immune-based vaccines for established HPV-associated diseases 
 
Although efficient prophylatic vaccines (Gardasil and Cervarix) that trigger 
protective immune responses against HPV infections have been designed and approved 
by the Health Authorities from different countries, the lack of knowledge on cervical cancer 
and HPV among the communities in developing countries restricts participation in a 
vaccination program. Furthermore, the cost of the vaccines is high which will hinder those 
with a low income from being able to afford the vaccination. As the female population in 
the developing countries continues to rise with an increase in life expectancy, it is 
expected that the number of cases of HPV-associated cancers will rise further in the years 
to come (48). Thus, development of new therapies for HPV persistently infected patients 
remains an important health and economic task.  
 
1.4.1 HPV E6 and E7 specific immune therapies 
 
It has been shown that the expression level of HPV L1 and L2 in cervical cancer or 
infected basal cells is undetectable. In contrast, the E6 and E7 proteins that are required 
for oncogenic processes increased with the severity of HPV-mediated neoplasia. 
Therefore, these oncoproteins have become potent targets for specific immune therapies 
which can activate cell-mediated immune response to eradiate HPV-associated lesions 
(49).  
 
 Peptide/protein vaccination targeting HPV oncoproteins 
Peptide/protein vaccination aims to boost tumor antigen specific CD4+ T cells and 
primed CD8+ effector T cells. Vaccination with overlapping synthetic E6 and E7 long 
peptide in patients with HPV16+ high-grade cervical squamous intraepithelial lesions 
resulted in enhanced infiltration of virus specific CD8+ T cells (50). Protein vaccines 
including HPV16.E7 protein covalently linked with a Mycobacterium bovis BCG-Heat 
shock protein (HSP) induced complete regression in 35% of patients with high-grade 
squamous intraepithelial  (HSIL) (51). However, most of peptide/protein-based strategies 
are unlikely to induce sufficient T cell responses against established and advanced 
disease stages (52). Indeed, a study using HPV16 E7 transgenic skin grafting model 
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reported that immunisation with E7 peptide was unable to induce graft rejection despite the 
induction of specific CD4+ and CD8+ T cells (53). One possible explanation for the failure 
of specific vaccine is that E7 expressing epithelial cells produce immunosuppresive 
molecules which can inhibit CTL-mediated graft rejection (42, 44, 54). Alternatively, 
trafficking of E7-specific CD8+ T-cell to skin might be impaired by this local suppressive 
environment. Furthermore, these effector cells may not respond optimally to immunization 
in an E7 graft recipient due to the ineffective antigen presentation (42).  
 
 DNA vaccine 
A DNA vaccine is constructed by introducing gene encoding HPV oncoproteins into 
a recombinant plasmid that enables the expression of these oncoproteins within 
mammalian cells. Consequently, these proteins can be delivered and packaged into MHC 
class I molecules in dendritic cells, thereby stimulating anti-tumor immune response by 
inducing cytolytic T cell (CTL) activity in CD8+ T cells (55).  
Although DNA vaccines are regarded as a safe, simple and stable antigen-specific 
therapy, there are still some concerns that HPV oncogenes might be integrated into the 
host genome and potentially induce oncogenic transformation by inhibiting tumor 
suppressor genes. DNA vaccines encoding a mutant HPV16.E7 protein in which three 
point mutant sites were introduced to the pRb binding motif of the E7 protein is designed to 
reduce the transforming activity. This strategy has been shown to provide an antitumor 
effect in the HPV16.E7 transplantable mouse model (55).  
 
 Dendritic cell- based vaccine 
To enhance cell-mediated immunity against HPV, dendritic cell-based vaccines 
have been developed by loading viral oncoprotein/peptide to autologous DCs. These cells 
are capable of taking up antigens, migrating to lymph nodes and priming specific CD4+ 
and CD8+ T cell responses (56). Human DCs which were isolated from HPV infected 
patients, and subsequently pulsed with tumor lysate and matured with dsRNA Poly [I]:poly 
[C] analogue, showed enhanced HPV specific CTL and T helper responses both in-vivo 
and in clinical trials. However, the DC-based vaccine is an expensive approach and cannot 
be produced in a large scale, thereby imposing limitations on its clinical applications (57).  
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1.4.2 Immunostimulatory adjuvant as a non-specific immunotherapy 
 
The efficacy of therapeutic strategies is dependent not only on the specific immune 
response to viral antigens but also on the inflammatory environment. Immunostimulants 
are thought to activate the innate immunity and are essential for a sufficient and durable 
adaptive immune response. In this perspective, increasing evidence has demonstrated 
clinical benefits of immune adjuvants in HPV-associated lesions. 
 
 Listeria monocytogenes-based vaccine  
The administration of Listeria bacteria around the time of grafting (4 days before or 
8 days after grafting) is capable of breaking tolerance and triggering the rejection of the 
K14.E7 graft. This immunotherapy strategy is involved in complex action mechanisms that 
stimulate innate and cell-mediated immunity while reducing immunosuppressive (58). In 
fact, the rejection of the HPV16.E7 skin graft is promoted by the release of 
proinflammatory cytokines, thereby activating the maturation of DCs and cross 
presentation of keratinocyte-derived E7 protein (27). Furthermore, vaccination with 
immunotherapeutic Listeria induces IFNγ and IFNγ-dependent chemokines production, 
resulting in the enhanced migration of tumor-infiltrating T cells in the TC1 transplantable 
tumor model (59). Thus, an efficient innate response stimulated by Listeria may assist the 
regression of HPV-associated lesions. Several clinical trials are conducted to examine the 
efficacy of Listeria-based vaccine for the treatment of HPV-related human cancers (60).  
However, cytokine-mediated toxicity and a course of antibiotic treatment to assure 
complete clearance of bacteria should be taken into account (61).  
 
 Imiquimod 
Imiquimod which is a TLR7 agonist, is capable of activating macrophages and 
mucosal DC to secrete pro-inflammatory cytokines including IFNα, TNFα and IL-12 (62). 
These cytokines have been shown to promote antigen presentation and maturation of LCs. 
In phase III trial, application of imiquimod induced complete regression of genital warts 
without recurrence following treatment (63).  
 
 2,4-Dinitrochlorobenzene (DNCB) 
Contact hypersensitivity induced by topical application with DNCB, an allergen, was 
first described as an effective therapy for malignant melanoma in the early 1970s (64). In 
addition, it was also used to treat condylomata acuminata caused by HPV infection. A 
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clinical study reported that 13 of 15 patients exhibited complete clearance of lesion 
following DNCB treatment (65). Additionally, DNCB was recognised as a potent therapy for 
resistant warts caused by HPV. However, the use of DNCB for treatment has been 
discouraged because of its mutagenic and carcinogenic potential (66). Furthermore, the 
mechanisms of action for DNCB as an immunotherapeutic modality are poorly understood. 
It is speculated that understanding how induction of a vigorous acute inflammatory 
response can break the locally immunosuppressive environment caused by HPV and 
restore the effector function of adaptive immunity, might lead to more acceptable 
treatments for persistent HPV infection. 
 
1.5 Mechanisms of DNCB-induced cutaneous inflammation 
 
1.5.1 Activation of T-cell mediated immune response 
 
DNCB-induced contact hypersensitivity is thought to be a T cell mediated-process. 
There are two distinct phases to achieve effective T cell-mediated immunity. In the 
sensitization phase, the skin is exposed to low-molecular weight allergens such as DNCB 
that undergo the haptenation process by forming covalent bonds with lysine, tyrosine, 
histidine and cysteine groups of epidermal cell proteins. Haptenated proteins are highly 
immunogenic and taken up by LCs, antigen presenting cells in the skin. These cells 
subsequently migrate to skin draining lymph nodes where they cross-present haptenated 
peptides to CD4+ and CD8+ T cells (Figure 1.3) (67).  
When the skin is re-exposed to an allergen, the elicitation phase is initiated, in 
which primed CD4+ and CD8+ T cells are expanded, enter the circulation and home to the 
site of inflammation. Once entering the skin, CD4+ and CD8+ T cells show different effector 
functions. Activated CD8+ T cells produce IFN-γ which has been shown to promote other 
cytokines and chemokines production and exert cytotoxic activity in contact 
hypersensitivity, while CD4+ helper T cells including Th1/Th2/Th17 and regulatory T cells 
are both important mediators and regulators of contact hypersensitivity   (68, 69).  
Not only CD8+ T cells, CD4+ Th1 cells were also shown to produce IFNγ in contact 
hypersensity.  In vivo depletion of IFNγ production by CD4+ Th1 cells in C57BL/6 mice 
caused impaired CHS responses to DNFB and oxazolone compared with wild-type 
animals (70).  
Th2 cytokine IL-4 is predominantly regarded as negative regulators of the DNCB-
induced inflammatory response (71, 72). However, these cytokines have been shown to 
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be responsible for the amplification and chronicity of allergic skin inflammation in a mouse 
model of allergic skin inflammation. Deficiency in these cytokines in these mice displayed 
an impaired ear swelling response to DNCB application (73, 74).  
Regulatory CD4+ T cells have been shown to promote resolution of contact 
hypersensitivity. In deed, depletion of regulatory T cells increases the level and duration of 
the contact hypersensitivity response.  Furthermore, this cell subset has been shown to 
reduce the number of IFNγ-producing CD8 T cells (75). IL-10 produced by Treg is also 
responsible for alleviated inflammatory response to contact allergen (76).   
 
Figure 1.3- The mechanism of action of allergic contact hypersensitivity. The 
sensitization and elicitation phase of contact hypersensitivity are outlined. Sensitization 
phase (step 1-4). (1) Hapten applied to the skin is haptenated with self-proteins and 
haptenated proteins are taken up by LCs. (2) These LCs migrate to the skin draining 
lymph node and (3) present antigen to both CD4+ and CD8+ T cells.  (4) Hapten-specific T 
cells are expaned in the lymph node and circulate via efferent lymph and home to the site 
of inflammation. Elecitation phase (step 5-7). (5) When the skin is re-exposed to the 
same hapten, DC and keratinocytes present haptenated peptides to specific T cells. (6) 
Activated CD8+ T cells exert CTL activity, induce apoptosis of KCs and promote 
proinflammatory cytokines and chemokines. (7) CD4+ T cells are differentiated into 
Th1/Th2/Th17 or Treg which produce both pro-inflammatory and anti-inflammatory 
cytokines.  Adapted from (77).  
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The cytokine milieu produced during inflammation to hapten is far more complex 
than a simple Th1/Th2 paradim would explain (78). Th17 T cells, a distinct subset of CD4+ 
helper T cells which secrete IL-17A, IL-17F, IL-21 and IL-22, have been recently emerged 
as important effector cells of contact hypersensitivity (79, 80). The differentiation and 
maturation of this subset are orchestrated by transcriptional factors including RORγt and 
STAT3, respectively (81). Th17 cells differentiation are regulated by a complex signaling 
network. In studies using murine models, inflammasome activated IL-1β and IL-18 were 
shown to induce the differentiation of Th17 cell (82). Furthermore, IL-6 when combined 
with TGFβ was described as the strongest inducer of Th17 cell differentiation while IL-23 is 
thought to act on the expansion, maintenance of Th17 cells (83). 
IL-17A signals through a receptor complex composed of IL-17RA/IL-17RC and 
plays a pivotal role in inflammatory response to 2,4-dichloronitrobenzene (DNFB), an 
analog of DNCB. Studies using experimental models of contact hypersensitivity 
demonstrated that IL-17A-/- mice developed alleviated ear swelling response to allergen 
compared with wild-type mice (84, 85). In these studies, IL-17A was reported to induce 
hyperinflammation and recruitment of macrophages and neutrophils to the skin (84, 85). 
Furthermore, in adoptive transfer experiments, CD4+ T cells isolating from IL-17A sufficient 
mice animals can recover the inflammatory response in IL-17A deficient animals (86). 
Thus, IL-17A-derived CD4+ T cells is an important mediator in allergen induced 
inflammation. Furthermore, T cell-derived IL-17A was shown to stimulate cytokine 
production including granulocyte macrophage colony-stimulating factor (GM-CSF), IL-6 
and intercellular adhesion molecule (ICAM-1) expression by human keratinocytes, thereby 
amplifying the nickel-induced skin inflammatory response (87). A recent study has 
reported that exposure to DNFB results in IL-1β release by keratinocyte which in turn 
activates γδT, particularly dendritic epidermal T cells, to produce IL-17A and subsequently 
drive inflammatory response (86). Interestingly, IL-17A has been recently shown to 
mediate the Th2 inflammation in a murine model of atopic dermatitis, a chronic skin 
inflammatory disease (88).  
In summary, topical application of DNCB leads to the activation of T cell-mediated 
immune response that is manifested by the production of T cell-derived cytokines. It has 
been shown that different types of allergens results in different cytokine profile responses. 
Contact allergens such as DNFB, oxazolone and DNCB preferentially induce Th1-
predominant responses, whereas allergens such as trimellitic anhydride and FITC might 
induce Th2-predominant responses (70). Additionally, IL-17A produced by Th17 cells has 
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been recently described as an important mediator of inflammatory response to various 
contact allergens (78, 80).  
 
 1.5.2 Stimulation of innate immunity 
 
Although activation of T-cell mediated immune responses is the proposed mechanism of 
the clinical effect of DNCB, there is limited data concerning innate immunity mechanisms. 
Acute cutaneous inflammatory response to DNCB is initiated by the secretion of IL-1β and 
IL-18 by KCs and DCs. These cytokines are first produced as inactive precursors in the 
cytoplasm and then cleaved into active forms by caspase-1 activity which is driven by a 
multiprotein complex, known as inflammasome. Allergen application triggers epidermal 
cells to release extracellular danger signals (ATP, ROS and low-molecular weigh 
hyaluronic acid) which are implicated in the activation of NALP3 inflammasome (89, 90). 
Activation of NALP3 inflammasome causes secretion of active proinflammatory cytokines 
including IL-1β and IL-18 which are crucial for DC maturation and migration (91). 
Additionally, production of these cytokines during sensitization phase is critically required 
for hapten-specific and non-specific proliferation of draining lymph node cells (92). Indeed, 
the role of the inflammasome was confirmed in NALP3 deficient mice which developed 
impaired contact hypersensitivity response to allergens (91). The regulation of NALP3 
activation by danger signals is largely unknown. A recent study by Guadar et al. suggested 
that type I IFN (IFNα and IFNβ) inhibit the activation of the NLRP3 inflammasomes in a 
STAT1 transcription factor dependent manner, thereby suppressing caspase-1-dependent 
IL-1β maturation (93) 
Furthermore, application of DNCB to rat skin caused migration and activation of 
peripheral blood granulocytes which produced nitric oxide (NO) and TNFα (69). Dendritic 
cells, particularly LC cells in the skin, are crucial arms of innate immunity. DNCB 
application leads to the induction of costimulatory molecule CD86, class II MHC molecules 
and secreted cytokines including IL-12, IL-6 and IL-23 in these cells which subsequently 
could drive T cell polarization (94).  
Topical immunotherapy with DNCB might thus be an additional treatment approach 
that works by inducing a vigorous acute inflammation and stimulating T cell-mediated 
immune response which in turn can break the tolerance induced by HPV persistent 
infection.  
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1.6 Dual regulatory roles of arginase in innate immunity 
 
1.6.1 Introduction to arginase 
 
 Arginase and L-arginine metabolism 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4- L-arginine metabolism by iNOS and Arginase-1. Arginase-1 and iNOS 
(NOS2) are the key mediators of L-arginine metabolism. Arginase-1 converts L-arginine 
into urea and L- Ornithine which is further required for the synthesis of important 
intermediate products (Putrescine and L-proline) for cell division and collagen synthesis. 
NOS2 (iNOS) metablizes L-arginase into Nω-OH-L-arginine, and then Nω-OH-L-arginine 
is transduced to form NO and L-citruline which are further converted to reactive nitrogen 
oxides. ARG1: Arginase-1; ODC: Ornithine decarboxylase; OAT: Ornithine 
aminotransferase; NO: Nitric oxide; NOHA: Nω-OH-L-arginine. Adapted from  (95).   
 
L-arginine is regarded as a non-essential amino acid because it can be synthesized 
by epithelial cells of the small intestine and the proximal tubules of the kidney from 
citrulline. However, in certain physiological conditions such as trauma and infection, this 
amino acid becomes conditionally essential. L-arginine is transferred to the inner cell 
compartment via the y+ system of cationic amino acid transporters. Once in the cells, L-
arginine is metabolized by either arginase or nitric oxide synthases (NOS) (95). While NOS 
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converts L-arginine into citrulline and NO, arginase catalyzes the hydrolysis of L-arginine 
into urea and L-ornithine. L-ornithine is further metabolized into either polyamines 
(putrescine, spermidine) or L-proline by ornithine decarboxylase and ornithine 
aminotransferase, respectively. Polyamines are implicated in cell proliferation and 
differentiation while L-proline is essential for the synthesis of collagen. L-argnine can be 
recycled from L-citrulline via argininosuccinate synthase and argininosuccinate lyase (96) 
(Figure 1.4). 
 
 The distribution of arginase  
Mammalian arginase consists of two isoforms: arginase-1 and arginase-2 which are 
encoded by two distinct genes and are different in their tissue distribution and subcellular 
localization. Arginase-1 is a cytoplasmic and inducible isoform which is strongly expressed 
in liver and constitutes the majority of total body arginase activity. In contrast, arginase-2 is 
a mitochrondrial isoform which is constitutively expressed in various mammalian tissues 
including kidney, prostate, small intestine and the lactating mammary gland. Both isoforms 
are induced in murine macrophages, and myeloid derived suppressive cells (MDSCs) in 
response to different stimuli. In skin, both isoforms are expressed in keratinocytes, 
fibroblasts. Arginase activity in skin is located predominantly in the epidermis (97). In 
humans, arginase activity can be detected in serum of patients with colorectal, breast, 
prostate and skin cancer. Additionally, arginase can also be expressed either by tumor 
cells or tumor associated myeloid cells (98). 
 The regulation of arginase expression 
Arginase-1 expression in myeloid cells can be induced by a variety of factors. 
ProstanglandingE2, GM-CSF, lipopolysaccharide (LPS) (99) and Th2 cytokines including 
IL-4, IL-10 and IL-13 are key inducers of arginase-1. These molecules bind to their 
cognate receptors that in turn activate STAT6. This transcriptional activator binds to the 5’ 
flanking region and induces the expression of the arginase-1 gene (Figure 1.5). In addition, 
arginase-1 is also induced by mycobacteria through a STAT6 independent mechanism. In 
this mechanism, the presence of mycobacteria is detected by TLR which in turn activates 
MyD88 signaling pathway. This signal transduction pathway recruits the transcriptional 
factor CEBP-β instead of STAT6 to up-regulate expression of arginase-1 in macrophages 
(100). 
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Figure 1.5- Arginase expression is reciprocally regulated by Th1 and Th2 cytokines. 
While Th2 cytokines (IL-4; IL-13), IL-10, TGFβ and cyclic AMP induce the expression of 
arginase via STAT6 transcription factor, Th1 cytokines (IFNγ, TNFα), IL-1; IFNα and IFNβ 
induce iNOS (NOS2) via STAT1 transcription factor and downregulate arginase-1 
expression. Adapted from (95).  
 
Arginase-1 expression in myeloid cells is negatively regulated by the Th1 cytokine 
IFNγ which induces iNOS expression. The induction of iNOS in macrophages results in the 
inhibition of arginase expression due to the competition for the common substrate L-
arginine. Moreover, the production of NO by iNOS might abrogate the induction of 
arginase-1 mediated by IL-4 and IL-10. However, LPS which is known as an inducer of Th-
1 cytokines has been shown to induce arginase-1 expression in macrophages (101). In 
addition, Liscovsky et al (2009) showed that the induction of arginase in murine 
macrophage by oligodeoxinucleotides containing CpG motifs is dependent on the 
production of IFNγ (102). 
 
1.6.2 Myeloid derived suppressor cell (MDSC) derived-Arginase- an immune 
suppressive factor 
 
 Arginase and T cell function 
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Figure 1.6- Arginase induces T cell dysfunction. COX-2/PGE2 produced by tumor cells 
activates MDSCs to express arginase-1, thereby depleting L-arginine in the milieu. 
Depletion of L-arginase by arginase-1 leads to the suppression of T cell function by 
dampening the synthesis of CD3ζ and cdk4 in T cells. Adapted from (103).  
 
MDSCs are heterogenous populations of immature myeloid cells comprising 
macrophages, granulocytes and dendritic cells. They accumulate in the blood, lymph 
nodes, bone marrow and tumor environment in most patietnts and experimental animals 
with cancer. MDSCs are capable of inducing T cell dysfunction by suppressing the 
activation and  proliferation of CD4+ and CD8+ T cells (104) or indirectly by promoting the 
differentiation of Treg (105).  
MDSC infiltration has been shown to be associated with the progressive course of 
HPV-induced cancer (106, 107). A recent study has reported that MDSCs are increased in 
number in blood from patients with HPV-associated oropharyngeal cancer. After 
chemoradiotherapy, these patients showed a remarkable increase in the number of 
circulating MDSC and loss of HPV specific T cell responses (106). Interestingly, HPV16 E2 
protein expresssed in squamous cell carcinoma cell line reduces the proportion of MDSCs 
and the production of MDSC-related mediators including iNOS and IDO, leading to 
enhanced anti-tumor responses (108). However, the precise role of MDSCs in HPV-
associated cancer has not been addressed in these studies and requires further studies.  
Since the first study conducted in 1970, accumulating evidence has suggested that 
arginase is one of the most important mediators employed by MDSCs to dampen T cell 
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functions (95). Arginase expressed by MDSCs has been shown to modulate the function of 
T cells through the depletion of L-arginine in the surrounding milieu. The starvation of L-
arginine results in the activation of GCN2 kinase, which in turn induces the 
phosphorylation of translational factor eIF2α. Phosphorylated eIF2α subsequently binds to 
eIF2β with a strong affinity. In this case, eIF2α loses its ability to exchange GDP for GTP. 
Consequently, this eI2F complex is unlikely to activate methionine aminoacyl tRNA 
thereby blocking the initial step of the translational process in T cells (Figure 1.6). Indeed, 
the deprivation of L-arginine has been shown to induce the diminished synthesis of cyclin 
D3 and cyclin dependent kinase 4 leading to the loss of proliferation and ability to produce 
IFNγ in T cells (95). In addition, L-arginine is required for the synthesis of CD8 and CD3 
receptors. Depletion of L-arginine might result in impaired T cell receptor (TCR) signaling 
(109).  
Additionally, in the presence of low concentrations of L-arginine, arginase-1 and 
iNOS can synergistically induce T cell dysfunction. Arginase and iNOS expressed by 
MDSCs might accelerate the production of reactive nitrogen and oxygen species (RNS 
and ROS), respectively, which are toxic for T cells (95). Furthermore, co-expression of 
arginase and iNOS might lead to the production of peroxinitrites (ONOO2). This strongly 
reactive agent induces the nitration of TCR, thereby affecting its conformation flexibility 
and interaction with MHC molecules. As a result, the binding of peptide on MHC to CD8+ T 
cell is abrogated (103). 
 
 The regulatory effect of arginase on NOS function 
Three different isoforms of NOS (NOS1, NOS2 and NOS3) have been identified.  
NOS1 (neuronal NOS or nNOS) and NOS3 (endothelial NOS or eNOS) are constitutively 
expressed in neuronal tissues and endothelium, respectively, while NOS2 (cytokine-
inducible NOS or iNOS) is induced in several tissues and cell types, including 
macrophages, DCs and the vascular endothelium. NOS enzymes are known to convert L-
arginine to citrulline and nitric oxide (NO), which are essential for cytotoxic mechanisms to 
protect against infection (103). NO generated by iNOS induction has been shown to block 
T cell function by interfering with the IL-2 signaling pathway (109). In addition, iNOS 
expression is an important marker of classically activated macrophages (M1 macrophage) 
which are implicated in anti-tumor mechanisms. On the other hand, it has also been 
reported that NO promotes the tumor growth by stimulating neo-angiogenesis and 
metastasis.  
Chapter 1 
 
 23 
Although the co-expression of arginase and iNOS has been reported in MDSCs, 
arginase is more likely to function as a controller of iNOS activity in inflammatory 
monocytes (110). Firstly, endowed with higher capacity to catalyse the hydrosis of L-
arginine, arginase efficiently competes with iNOS for the common substrate. Therefore, in 
the limited availability of L-arginine, arginase is able to deplete the substrate in the 
extracellular environment, resulting in the inhibition of iNOS activity. Additionally, the 
deprivation of L-arginine has been shown to be responsible for the blockage of  the 
translational process and decreased stability of iNOS mRNA (95).  
A number of recent studies showed that arginase and iNOS participate in the 
maintenance of nonresolving or chronic inflammation in several disease models. “Danger 
signal” generated by trauma triggers the recruitment of iNOS expressing cells which are 
required for the clearance of dead cells and the re-epithelialization (111). Subsequently, 
MDSCs expressing arginase are recruited to the wound site and induce the synthesis of 
collagen mediated by fibroblasts which is crucial for tissue remodeling. Ariel et al. (2012) 
reported that arginase expressed by alternatively activated macrophages (M2 
macrophage) is implicated in the resolution of inflammation which protects wounded mice 
from excessive tissue repair (112). However, a malignant tumor tends to constantly cause 
tissue damage, which may result in depletion of L-arginine in the tumor environment and 
nonresolving inflammation (103). In addition, Kavalukas e. al. (2012) showed that inhibition 
of arginase promotes the production of NO and ultimately leads to the resolution of 
inflammation in wounded mice (96). Furthermore, L-arginine metabolism has been shown 
to play an important role in psoriasis, which is also known as a chronic inflammatory 
disease of the skin driven by IL-17A (113). This disease is manifested by the 
hyperproliferation and reduced differentiation of keratinocytes, which is mediated by the 
interplay between arginase-1 and iNOS. This study revealed that overexpression of 
arginase-1 contributes to the development of psoriasis by confining NO production (114). 
Thus, these studies have highlighted the immunosuppressive functions of arginase in 
chronic inflammation.  
 
  The potential implication of arginase for the establishment of persistent infection 
and tumorigenesis mediated by HPV infection  
Arginase might be implicated in the establishment of immunosuppressive 
environment or chronic inflammation that favors the persistent infection of HPV and cancer 
progression. This notion is supported by a recent study that demonstrates enhanced 
production of Th2 cytokine IL-13 and IL-10 in the serum of cervical cancer patients, 
Chapter 1 
 
 24 
coincided with an increase of arginase activity and depletion of L-arginine (115). 
Furthermore, Lepique et al (2009) showed that in a HPV-16 induced tumor mouse model 
(TC-1 model), macrophages expressing high level of arginase-1 facilitate tumor growth by 
dampening antitumor T cell function. In this study, the absence of tumor infiltrated 
macrophages accelerates the recruitment of T lymphocytes to tumor environment and 
delays tumor growth (116). In this regard, Coussens et al (2000) found that M2 
macrophages infiltrate the skin and mount chronic inflammation which promotes the 
progression from dysplasia to invasive cancer (117). Although arginase has been 
described as one of the most specific markers of the M2 macrophage (95), whether 
arginase is implicated in the progression of HPV associated cancer has not been 
demonstrated in this study. Thus, whether arginase is responsible for facilitating tumor 
growth has not been justified by these studies, despite its association with HPV-related 
tumors.  
It has been suggested that HPV-specific CD4 + and CD8 + T cells within a cervical 
cancer environment are functionally inactive. Mattarollo et al (2010) showed that skin 
infiltrated invariant natural killer T cells (iNKTs) are involved in the establishment of a local 
immune suppression environment that subvert CD8+ specific T cells in HPV16.E7 
expressing skin (44). However, the mechanism by which NKT cells are activated to exert 
their function is still a matter of ongoing research. A recent study by Terabe et al. (2000) 
has identified the cross-talk between NKT cells and MDSCs in the regulation of the 
immune response. In this study, they reported that IL-13 expressed by NKT cells can 
activate MDSCs to suppress T cell function. In addition, IL-13 is widely known as an 
inducer of arginase (118). Thus, arginase might be involved in the subvertion of the 
effector T cells in HPV persistent infection. 
In addition, arginase and iNOS coordinately contribute to the production of ROS 
(95). A recent study by Marco et al (2012) has shed the new light on the association of the 
production of ROS with HPV-16 neoplastic progression. This study indicated that the 
increased production of ROS results in the oxidative modification of cellular proteins and 
DNA damage. Consequently, these detrimental effects trigger the progression of a 
dysplasia lesion to cervical cancer (119).   
In summary, these findings lend support to the idea that arginase might be exploited 
by HPV to establish an immunosuppressive environment that facilitates the persistent 
infection and tumor development.  
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1.6.3 Arginase derived-monocytes/macrophages-an inducer of acute 
inflammation 
 
Arginase is not solely an immune-suppressive mediator. Recent studies have 
reported that arginase is an important stimulator in several inflammation episodes.  
Arginase-1 produced by macrophages has been shown to play critical role in the 
pathophysiology of asthma which is a complex disease manifested by allergic airway 
inflammation and airway hyperreactivity. In mouse models of asthma, arginase-1 mediated 
allergic inflammatory response in lung epithelial cells through the modulation of NFκB 
signaling pathway (120, 121). Furthermore, treatment with arginase specific inhibitor, 2(S)-
amino-6-boronohexonic acid (ABH), significantly ameliorated pulmonary inflammation and 
airway fibrosis in guinea pigs repeatedly exposed to LPS. The alleviated inflammation in 
these animals was concomitant with decreased IL-8 production and neutrophil infiltration 
(122).  
In vascular inflammation, arginase-1 efficiently competes with iNOS for the common 
substrate L-arginine, leading to inhibition of iNOS expression and NO production. Since 
endothelium-derived NO is reported to suppress expression of adhesion molecules such 
as VCAM-1, ICAM-1 (123), limiting NO bioavailability through arginase results in enhanced 
inflammation (124). Likewise, this mechanism action of arginase was further supported by 
a recent study that the blockade of arginase activity by another arginase inhibitor, alpha-
amino acid N(omega)-hydroxy-nor-l-arginine (nor-NOHA), resulted in alleviated 
inflammation, crypt damage via enhanced NO production in the colon tissue of  dextran 
sodium sulfate-induced colitis mouse model (125).  
In a mouse model of atherogenesis, arginase-2 but not arginase-1 enhances 
monocyte adhesion to endothelial cells and triggers the production of proinflammatory 
cytokines through mitochondrial reactive oxygen species (126). Liu et al. show that 
infiltrating myeloid cells produce arginase-1 which promotes angiogenesis and further 
recruitment of monocytes in laser-induced injury murine model (127).  
Taken together, arginase can enact either inhibitory or stimulatory effect on the 
immune system dependent on the inflammation context. In tumor environment, it has been 
well established that arginase-1 produced by MDSCs is an important immunesuppressive 
mediator which inhibit cell-mediated immunity. On the other hand, cells of myeloid cell 
origin are among the first components of the immune system that are recruited to the site 
of inflammation and arginase-1 produced by macrophages is responsible for the 
exacerbation of inflammatory response in epithelial and vascular inflammation. Although 
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arginase-1 has recently emerged as an important regulator of the inflammatory response 
in numerous disease models, the association between arginase and the clearance of HPV 
infection remains poorly understood.  
 
1.7 Purpose of the study 
 
Although the majority of HPV infections regress pontaneously, 10% of infections are 
persistent and eventually progress to invasive cancer. In addition, although recent 
vaccines (Gardasil and Cervarix) have been shown to efficiently protect against HPV 
infection, HPV vaccination is only targeted at adolescents who have not previously been 
exposed to HPV (128). Furthermore, the high cost of the vaccine hinders accessibility for 
those with a low income. Therefore, the development of effective immunological therapies 
which are able to prevent infected patients from developing a persistent infection and 
invasive cancer remains an important health and economic concern. 
DNCB-induced acute inflammation is speculated to alter the local immune-
suppressive environment induced by HPV oncoproteins. However, the mechanism action 
of DNCB in association with HPV infection is largely unknown. Furthermore, clinical 
application of DNCB therapy has been hampered due to its mutagenic and carcinogenic 
potentials. Therefore, the objective of this study is to understand the innate immune 
response to DNCB in model of HPV-associated squamous cancer, K14.E7 mice. Our 
findings might contribute to the development of better immune-based therapies for HPV 
persistently infected patients.  
 
1.8 Hypotheses and aims 
 
 This study investigated the following hypotheses: 
1. The expression of HPV16.E7 protein in the epithelium alters the levels and features of 
cutaneous inflammatory response to DNCB in K14.E7 mice as compared to wild-type 
mice.  
2. Arginase-1 and arginase-2, important regulators of innate immunity, are responsible for 
regulating the DNCB-induced inflammation in HPV16.E7 expressing skin. 
3. Inflammatory cytokines including Th2 cytokines/IL-6/IL-17A contribute to the induction of 
arginase and mediate DNCB-induced inflammation in HPV16.E7 expressing skin.  
 
 The aims of this study are to 
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1. Examine the ear swelling response, the inflammatory cell infiltrate and cytokine 
producing profile of wild-type C57BL/6 and K14.E7 skin exposed to DNCB and investigate 
the role of lymphocytes in DNCB–induced inflammation in K14.E7 mice. 
2. Analyse the production and the source of arginase-1/2, and their involvement in 
regulating DNCB -induced inflammation in K14.E7 mice. 
3. Investigate the production and involvement of Th1, Th2 and Th17 cytokines in the 
regulation of arginase-1/2 and DNCB-induced inflammation in K14.E7 mice.  
4. Examine the survival of K14.E7 skin grafts following DNCB treatment and E7 peptide 
vaccination. 
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HPV E7 Oncoprotein Transgenic Skin Develops An 
Enhanced Inflammatory Response To DNCB By 
Arginase-1-Dependent Mechanism 
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2.1 Foreword 
Stimulation of the innate immune system with DNCB is speculated to alter the local 
immunosuppressive environment induced by HPV. However, the immunostimulatory 
mechanism of DNCB in association with HPV-induced carcinogenesis has not been 
elucidated yet. The first aim of this chapter is to characterize the DNCB-induced inflammation 
in K14.E7 skin. As arginase has been shown to functions as an important regulator of 
inflammation and innate immunity, this chapter also aims to analyse the production, the 
source of arginase and its involvement in the regulation of DNCB-induced inflammation in 
K14.E7 skin. The work addressing these two aims has been published on Journal of 
Investigative Dermatology (2014) 134, 2438–2446. 
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Abstract 
 
We have shown that the expression of human papillomavirus type 16 E7 (HPV16.E7) 
protein within epithelial cells results in local immune suppression and a weak and ineffective 
immune response to E7 similar to that occuring in HPV-associated premalignancy and 
cancers. However, a robust acute inflammatory stimulus can overcome this to enable immune 
elimination of HPV16.E7-transformed epithelial cells. 2,4-Dinitrochlorobenzene (DNCB) can 
elicit acute inflammation and it has been shown to initiate the regression of HPV-associated 
genital warts. Although the clinical use of DNCB is discouraged owing to its mutagenic 
potential, understanding how DNCB-induced acute inflammation alters local HPV16.E7-
mediated immune suppression might lead to better treatments. Here, we show that topical 
DNCB application to skin expressing HPV16.E7 as a transgene induces a hyperinflammatory 
response, which is not seen in nontransgenic control animals. The E7-associated 
inflammatory response is characterized by enhanced expression of Th2 cytokines and 
increased infiltration of CD11b+Gr1intF4/80+Ly6ChiLy6Glow myeloid cells, producing arginase-
1. Inhibition of arginase with an arginase-specific inhibitor, Nω-hydroxy-nor-l-arginine, 
ameliorates the DNCB-induced inflammatory response. Our results demonstrate that 
HPV16.E7 protein enhances DNCB-associated production of arginase-1 by myeloid cells and 
consequent inflammatory cellular infiltration of skin. 
 
Abbreviations:  
 
CIN, cervical intraepithelial neoplasia; DNCB, 2,4-dinitrochlorobenzene; HPV, human 
papillomavirus; Nor-NOHA, Nω-hydroxy-nor-l-arginine; mRNA, messenger RNA 
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Introduction 
 
Persistent infection with oncogenic human papillomaviruses (HPV), particularly HPV16, 
is associated with selective expression of two virally encoded proteins (E6 and E7) (129). One 
action of HPV16.E7 protein is to subvert the innate immune system through the 
downregulation of IFNγ pathways, modulation of antigen presentation, and suppression of 
Toll-like receptor 9 protein (21). 
K14.E7 transgenic mice, which express HPV16.E7 oncoprotein within basal 
keratinocytes under the control of the keratin 14 transcriptional promoter, have been 
extensively used as a model of HPV oncoprotein–induced immune suppression associated 
with human squamous cancers, in which only the E6 and E7 genes of the papillomavirus are 
expressed (45). We have previously shown that skin grafts expressing HPV16.E7 oncoprotein 
are not spontaneously rejected when transplanted onto syngeneic animals, but they are 
rejected when certain components of the innate immune system are unavailable, confirming 
that the expression of HPV16.E7 in the epithelium results in the establishment of a local 
suppressive environment and the subversion of antigen-specific T cells (44, 54). Therefore, 
successful strategies targeting HPV-associated cancer need to circumvent or disrupt the local 
suppressive environment. 
Topical immunotherapies with immunostimulatory agents have been used clinically to 
treat cancerous lesions including squamous cell and basal cell carcinoma in 
immunocompetent and immunosuppressed patients (130). Topical application of 2,4-
dinitrochlorobenzene (DNCB) is an effective therapy for condylomata acuminata caused by 
HPV infection. DNCB induced the complete clearance of HPV-associated warts in 13/15 
patients (65). The efficacy of this treatment is attributed to the immunostimulatory role of 
DNCB that might activate cell-mediated immunity (69). However, the use of DNCB for 
treatment has been discouraged because of its mutagenic potential (66). We speculated that 
understanding how induction of a vigorous acute inflammatory response by DNCB can break 
the locally immune-suppressive environment and restore the effector function of adaptive 
immunity might lead to more acceptable treatments for persisting HPV infection. 
Arginase, which metabolizes l-arginine to N-ornithine and urea, has been identified as 
a crucial regulator of inflammation. Mammalian cells express two different isoforms, arginase-
1 and arginase-2, which are encoded by two distinct genes and are different in their tissue 
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distribution and subcellular localization (95). Arginase can function as an immunosuppressive 
factor in the tumor environment (131), in viral (132), or in parasitic infection (133). However, 
this enzyme has also been identified as an important proinflammatory factor in numerous 
disease models (134-136). As inflammation decides the fate of HPV infection and arginase is 
an important regulator of inflammation and immunity, we investigated the interaction between 
DNCB-induced inflammation and HPV16.E7 protein in induction of arginase in K14.E7 
transgenic mice. We show here that K14.E7 transgenic mice exhibit an enhanced local 
inflammatory response to DNCB treatment, compared with nontransgenic mice, and that 
myeloid cells express increased arginase-1, which specifically promotes DNCB-induced 
inflammation. 
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Results 
 
K14.E7 mice develop a robust inflammation response to DNCB 
 
An inflammatory response was induced in wild-type nontransgenic C57BL/6 and in E7 
transgenic K14.E7 mice by applying DNCB topically to the ear skin. The mean increase in ear 
thickness was monitored as an indicator of inflammatory reaction (137). K14.E7 mice 
displayed a significantly higher degree of ear swelling than C57BL/6 mice, which peaked at 
day 3 in response to a single application of DNCB (Figure 2.1a). 
T lymphocytes have been found in several skin inflammation diseases and have an 
important role in the production of inflammatory cytokines and in the recruitment of innate 
immune cells (138). They also drive the enhanced inflammatory response seen on repeated 
exposure to DNCB (70). In addition, our previous study showed that lymphocytes are 
increased in number in K14.E7 skin (139). Therefore, we investigated whether the enhanced 
inflammatory response to first exposure to DNCB in K14.E7 skin was dependent on local 
lymphocyte function. K14.E7 mice deficient in lymphocytes (Rag−/− ×E7), when exposed to 
DNCB, exhibited a similar level of ear swelling as K14.E7 mice, and stronger than control 
Rag−/− mice over 5 days after DNCB treatment (Figure 2.1a). Thus, DNCB-treated K14.E7 
mice exhibit a hyperinflammatory response on first exposure to DNCB, which is independent 
of an adaptive immune response. 
 
DNCB-treated K14.E7 skin displays an enhanced infiltration of myeloid cells and Th2 
cytokine expression 
 
To characterize further the inflammation in DNCB-treated K14.E7 skin, we examined 
the infiltration of immune cells. Histological examination suggested that the greater ear 
swelling in K14.E7 mice corresponded to a significant increase in the number of immune cells 
infiltrating the dermis (Figure 2.1b). As expected, the thickness of the K14.E7 epidermal layer 
remained unchanged following DNCB treatment (control: 42.4±3.7 μm, DNCB: 40±3.5 μm, 
Supplementary figure 2.1). Rag−/− × E7 mice develop similar ear swelling and inflammatory 
cell infiltration in the dermis as K14.E7 mice, whereas control Rag−/− mice do not (Figure 2.1a 
and b). Thus, the increased ear swelling in K14.E7 in response to DNCB mice was mainly 
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contributed by infiltration of cells of the innate immune system in the dermis, and it was 
independent of lymphocytes. 
Flow cytometry analysis revealed that DNCB-treated K14.E7 ears recruited 
significantly higher numbers of myeloid cells (CD45.2+CD11b+) than similarly treated C57BL/6 
ears. We observed the same trend when we compared Rag−/−xE7 mice with Rag−/− mice 
(Figure 2.2a). In contrast, the number of non-myeloid bone marrow–derived cells 
(CD45.2+CD11b−) remained unchanged and was comparable in all four groups following 
DNCB treatment (Figure 2.2b). Thus, the expression of HPV16.E7 in the skin mediates the 
enhanced recruitment of myeloid cells, and this effect is independent of adaptive immunity. 
IL-1β and IL-6 are major cytokines secreted from the local inflammation site and 
promote the recruitment of innate immune cells (140, 141). DNCB treatment resulted in a 
significant increase in IL-1β messenger RNA (mRNA) expression in both C57BL/6 and 
K14.E7 skin (Table 1). In addition, IL-6 mRNA expression was significantly increased in 
DNCB-treated K14.E7 skin but not in nontransgenic skin, suggesting that IL-6 might be 
responsible for the enhanced recruitment of myeloid cells in K14.E7 skin. 
Further, DNCB treatment of K14.E7 mice significantly induced mRNA expression of 
prostaglandin E2 synthase and Th2 cytokine IL-4 and IL-10. In contrast, there was no 
significant change in the expression of these factors in DNCB-treated C57BL/6 mice. Th1 
cytokines displayed decreased (tumor necrosis factor-α) or unaltered (interferon gamma) 
expression after DNCB treatment (Table 1).  
Together, these results suggest that after a single DNCB treatment to previously 
unexposed animals, K14.E7 mice mounted an enhanced inflammatory response, which is 
accompanied by CD45.2+CD11b+ myeloid cell infiltration and amplified Th2 cytokine 
expression. 
 
Arginase-1 is specifically induced in DNCB-treated K14.E7 mice 
 
Inflammation and myeloid cell activation can be associated with the induction of 
arginase (109). We speculated that arginase activity might contribute to enhanced 
inflammation of K14.E7 skin in response to DNCB. To test this hypothesis, we first 
investigated arginase activity in the skin of C57BL/6 and K14.E7 mice following DNCB 
treatment. Arginase activity was comparable in control K14E7 and C57BL/6 ear skin (Figure 
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2.3a), as was arginase mRNA expression (Figure 2.3b and RNAseq data not shown). DNCB-
treated K14.E7 skin, however, demonstrated a substantially higher amount of arginase 
activity than DNCB-treated C57BL/6 skin (Figure 2.3a). Arginase activity is contributed by two 
arginase isoforms. Increased arginase activity in K14.E7 mice corresponded to markedly 
increased (fourfold) arginase-1 mRNA expression. Conversely, the expression of arginase-1 
mRNA remained unchanged in DNCB-treated C57BL/6 mice (Figure 2.3b). In contrast to 
arginase-1, there was no significant induction of arginase-2 mRNA in either C57BL/6 or 
K14.E7 skin (Figure 2.3c). 
 
Arginase-1, but not arginase-2, is induced in K14.E7 mice following 2,4-
dinitrochlorobenzene (DNCB) treatment, and this regulation is lymphocyte 
independent.  
 
K14.E7 mice lacking lymphocytes (Rag−/− ×E7) not only exhibited a similar level of ear 
swelling as K14.E7 mice but also of arginase-1 mRNA and arginase activity following DNCB 
treatment. Notably, Arginase-1 and arginase-2 mRNA expression are not increased in control 
Rag−/− mice following DNCB treatment (Figure 2.3b and c). Thus, the induction of arginase in 
K14.E7 skin is independent of adaptive immunity. 
To examine whether the induction of arginase was unique to skin expressing 
HPV16.E7 oncoprotein as a transgene, K14.hGh and K5.OVA mice expressing human growth 
hormone or ovalbumin, respectively, under the control of keratin promoters were treated with 
DNCB. In contrast to K14.E7 mice, there was no change in the level of arginase activity of 
K14.hGh or K5.OVA mice following DNCB treatment (Figure 2.3d). Furthermore, the ear 
swelling of these transgenic mice (K5.OVA: 22.5±5 μm; K14.hGh: 17.5±5 μm, day 5) was 
similar to that of C57BL/6 mice (17.5±5 μm, day 5) and markedly lower than in K14.E7 mice 
(198±99 μm, day 5) (Supplementary figure 2.2). Thus, these results suggest that increased 
arginase activity, likely derived from activated myeloid cells, might be a consequence of 
exposure of K14.E7-expressing epithelial cells to DNCB. 
 
CD11b+Gr1intF4/80+Ly6ChiLy6Glow cells are the major source of arginase-1 in DNCB-
treated K14.E7 mice 
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Arginase-1 can be induced in myeloid cells including macrophages, dendritic cells, and 
myeloid-derived suppressive cells in response to a wide range of stimuli (142, 143). These 
myeloid cells express surface CD11b(144). To confirm whether myeloid cells were the source 
of DNCB-induced arginase-1 in K14.E7 skin, CD45.2+CD11b− and CD45.2+CD11b+ cells 
(Supplementary Figure S2.4) were isolated from DNCB-treated C57BL/6 and K14.E7 mice 
and analyzed for arginase activity and arginase-1 mRNA expression. CD11b+ myeloid cells 
from DNCB-treated K14.E7 mice produced significantly higher levels of arginase activity per 
cell compared with CD11b− cells, and compared with CD11b+ myeloid cells from DNCB-
treated C57BL/6 mice (Figure 2.4a). In addition, arginase-1 mRNA expression was 
substantially detected in CD45.2+CD11b+ cells in DNCB-treated K14.E7 mice, but not in 
CD11b−or CD11b+ cells from C57BL/6 mice (Figure 2.4b). Although arginase-2 mRNA was 
also detected in CD45.2+CD11b+ cells in K14.E7 skin, arginase-2 mRNA expression was 10 
times lower than arginase-1 (Figure 2.4b). Thus, DNCB-activated myeloid cells 
(CD45.2+CD11b+) produce the increased arginase-1 observed in DNCB-treated K14.E7 skin. 
CD11b is expressed on different myeloid subsets including macrophages/monocytes 
and granulocytes. To further define which cell subset expresses arginase-1 in DNCB-treated 
K14.E7 mice, we examined the expression level of arginase-1 in different populations of 
CD11b+ cells based on the expression of macrophage marker F4/80 and granulocyte marker 
Gr1. We found that F4/80+Gr1int cells expressed significantly higher levels of arginase-1 than 
other cell populations (Figure 2.4c). Furthermore, arginase-1 was abundantly expressed in 
inflammatory monocytes that express Ly6ChiLy6Glow but not in Ly6ClowLy6Ghi granulocytes 
(Figure 2.4d). 
 
Suppression of arginase ameliorates the ear swelling of inflamed K14.E7 skins 
 
Arginase can be paradoxically involved in the upregulation or downregulation of 
inflammatory responses. N(omega)-hydroxy-nor-l-arginine (nor-NOHA), which is an 
intermediate in the l-arginine/NO pathway, is widely used as a specific, reversible inhibitor of 
arginase both in vitro and in vivo (145, 146). To understand whether arginase promoted or 
suppressed the inflammatory response of K14.E7 mice to DNCB, we administered nor-NOHA 
or saline buffer to K14.E7 mice 1 day before DNCB treatment and daily for 4 days. 
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Ear tissue was harvested after 24 hours of DNCB treatment with or without arginase 
inhibitor, and the expression and activity of arginase were determined. Nor-NOHA, as 
expected, did not suppress the transcription of arginase-1 gene (Figure 2.5a), but caused a 
concentration dependent inhibition of arginase activity in DNCB-treated K14.E7 ear skin 
(Supplementary figure 2.5). Increasing dose of nor-NOHA from 100 μg/mouse (used by Bratt 
et al. 2009) to 500 µg/mouse (used in this study) improved the inhibitory efficacy in DNCB 
treated K14.E7 ear skin (Figure 2.5b). 
 
Furthermore, swelling of DNCB-treated K14.E7 skin was reduced in animals treated 
with arginase inhibitor (Figure 2.5c). Consistent with the ear swelling data, arginase inhibition 
decreased the number of infiltrating cells in the dermis of DNCB-treated K14.E7 mice (Figure 
2.5d and e). These results demonstrate that arginase-1 induced by DNCB in K14.E7 
transgenic ear skin, but not in C57BL/6 ear skin, itself contributes to exacerbated 
inflammatory response to DNCB in K14.E7 skin by recruitment of further inflammatory cells. 
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Figure 2.1- K14.E7 mice exhibit an enhanced inflammatory response to 2,4-
dinitrochlorobenzene (DNCB). Ear swelling of C57BL/6, K14.E7, Rag−/−, and Rag−/− × E7 
mice in response to DNCB or vehicle over 5 consecutive days (a) measured by caliper. Data 
are means±SEM, and are representative of two independent experiments with four mice per 
group. ***P<0.001. Histology of representative sections from C57BL/6, K14.E7, Rag−/− × E7, 
and Rag−/−mice (b) at 1 day post DNCB or vehicle application. Hematoxylin and eosin stain, 
original magnification × 200, scale bar=100 μm (representative of four mice per group). 
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Table 1- Expression of cytokine mRNA in response to DNCB or vehicle in K14E7 and 
C57 mice 
 Expression relative to housekeeping gene RPL32   
 C57BL/6 K14.E7  
Cytokine Vehicle DNCB Vehicle DNCB P 
IL-1β ( × 104) 6.8±0.8 51±4 221±132 1490±900 #, +, *, @ 
IL-6 ( × 104) 50±8 55±29 142±103 5310±2870 +, @ 
IL-4 ( × 1011) 1.3±2.2 3.0±3.1 15.1±14.2 74.5±53.3 +, @, * 
Ptge2s ( × 104) 75±74 91±127 158±34 480±124 +, @ 
IL-10 ( × 104) 0.4±0.3 0.8±0.8 4.0±1.1 7.0±1.6 +, * 
IFNγ ( × 104) 0.2±0.2 0.11±0.12 1.9±1.1 1.1±0.9 * 
TNFα ( × 104) 3.2±2.9 2.7±1.6 41.3±15.2 3.4±2.2 *, @ 
 
Abbreviations: DNCB, 2,4-Dinitrochlorobenzene; mRNA, messenger RNA; Ptge2s, 
prostaglandin E2 synthase; TNFα, tumor necrosis factor-α. 
 #P<0.05 C57 DNCB versus vehicle. 
 +P<0.05 K14E7 DNCB versus vehicle. 
 *P<0.05 K14E7 vehicle versus C57 vehicle. 
 @P<0.05 change in expression for DNCB-treated K14E7 versus DNCB-treated C57. 
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Figure 2.2- K14.E7 mouse skin has an enhanced myeloid cell infiltration in response to 
2,4-dinitrochlorobenzene (DNCB). Absolute counts of leukocyte cells in the skin of C57BL/6 
(n=4), K14.E7 (n=6), Rag−/− (n=5), and Rag−/− × E7 (n=5) mice following DNCB treatment. 
Absolute numbers of CD45.2+CD11b+ myeloid cells (a) and CD45.2+CD11b− cells (b) were 
determined by flow cytometry. Data are presented as means±SEM and are representative of 
two independent experiments. NS, not significant. **P<0.01, ***P<0.001. 
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Figure 2.3- Arginase-1, but not arginase-2, is induced in K14.E7 mice following 2,4-
dinitrochlorobenzene (DNCB) treatment, and this regulation is lymphocyte 
independent. Arginase activity was measured by determining the release of urea product 
from 100 μg of protein lysate per sample. Protein lysates were prepared from ear tissues of 
DNCB or vehicle-treated C57BL/6, K14.E7, Rag−/−, Rag−/− × E7, K14.HgH, and K5.OVA ear 
tissues. Relative gene expression levels of (b) arginase-1 and (c) arginase-2 messenger 
RNAs were determined by real-time PCR in the skin of C57BL/6, K14.E7, Rag−/−, and 
Rag−/− × E7 mice 1 day following DNCB treatment, normalized against the housekeeping 
gene RPL32. Data are presented as means±SEM and are representative of two independent 
experiments (n=4 mice per group). NS, not significant. *P<0.05. 
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Figure 2.4- CD11b+Gr1intF4/80+Ly6GlowLy6Chicells produce arginase in 2,4-
dinitrochlorobenzene (DNCB)-treated K14.E7 skin. Arginase activity produced by 
CD45.2+CD11b+ and CD45.2+CD11b− populations from DNCB-treated C57BL/6 and K14.E7 
mice (a) was determined as described in Materials and Methods. Arginase-1 and arginase-2 
mRNA expression (b) levels were determined by real-time PCR. Arginase-1 messenger RNA 
(mRNA) expression levels in Gr1−F4/80+; Gr1intF4/80+; Gr1hiF4/80+; and Gr1−F4/80− subsets 
from DNCB-treated K14.E7 mice were determined (c) by real-time PCR. Real-time PCR 
analysis of arginase-1 mRNA expression in different cell subsets (d) was based on the 
expression of Ly6C and Ly6G antigens. Data were pooled from four independent 
experiments. In each experiment, six C57BL/6 and two K14.E7 mice were treated with DNCB 
or vehicle. Means±SEM. NS, not significant. *P<0.05. 
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Figure 2.5- Inhibition of arginase ameliorates the ear swelling of dinitrochlorobenzene 
(DNCB)-treated K14.E7 mice. Mice were injected with 500 μg of arginase inhibitor (Nω-
hydroxy-nor-l-arginine (nor-NOHA)) or saline buffer 1 day before DNCB treatment and daily 
for 5 days. Arginase-1 messenger RNA (mRNA) expression (a) and arginase activity (b) in 
saline or nor-NOHA-treated K14.E7 mice after 24 hours of exposure to DNCB, determined by 
real-time PCR and arginase assay, respectively. Ear swelling of K14.E7 mice treated with 
saline (solid line) or nor-NOHA (dashed line) monitored during 5 days after DNCB treatment 
(c). Histological sections (d) and quantification of cell numbers infiltrating into the dermis from 
Nor-NOHA or saline-treated K14.E7 skins 1 day following DNCB application (e). 
Means±SEM, data show results from two independent experiments (n=5). NS, not significant; 
PBS, phosphate-buffered saline. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
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Supplementary figure 2.1- Dermal thickness but not epidermal thickness is augmented 
in both K14.E7 and Rag-/-xE7 mice following DNCB application. 
The average thickness of epidermis and dermis of vehicle or DNCB treated K14.E7 mice (n=6 
mice) determined by using images of Hematoxylin and Eosin stained sections. Ten fields 
counted per mouse were selected randomly and the epidermal and dermal thickness were 
determined by using NIS Elements imaging software version 3.2 (Nikon). Data presented 
indicate means ± SEM. ** p<0.01, NS nonsignificant. 
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Supplementary figure 2.2- K14.E7; K14.HgH and K5.OVA mice displayed similar level of 
ear swelling following DNCB treatment. 
The ear swelling of K14.E7; K14.HgH and K5.OVA mice (n=4 mice per group) within four 
consecutive days. Data presented indicate means ± SEM,** P<0.01, *** P<0.001.  
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Supplementary figure 2.3- Th2 cytokine IL-5 and IL-13 production in K14.E7 skin 
remains unchanged following DNCB application. Relative gene expression levels of (b) 
IL-5 and (c) IL-13 messenger RNAs were determined by real-time PCR in the skin of 
C57BL/6, K14.E7 1 day following DNCB treatment, normalized against the housekeeping 
gene RPL32. Data are presented as means±SEM. NS, not significant. *P<0.05. 
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Supplementary figure 2.4- Representative flow cytometry dot plots illustrating gating 
strategy and post-sort purity of CD45.2+CD11b+ and CD45.2+CD11b+ cell populations. 
(a) Equal number of CD45.2+CD11b+ and CD45.2+CD11b- subset was sorted from C57BL/6 
or K14.E7 mice after one day of DNCB treatment (upper panel) and post-purity of each 
subset was accessed (lower panel). (b) and (c) Gating strategy and post-sort purity of 
different myeloid subsets based on the expression of F4/80 and Gr1 (b) or Ly6C and Ly6G 
antigens (c). 
 
 
 
 
 
 
 
 Gated on viable CD45.2
+
 cells 
 
Gated on viable CD45.2+CD11b+ cells 
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Supplementary figure 2.5- Concentration effect of nor-NOHA on arginase activity in 
DNCB treated K14.E7 skin.  K14.E7 mice (n=4) were injected i.p. with 500 µg, 100 µg of nor-
NOHA or saline buffer (PBS) alone. The treatment was repeated two hours prior 
DNCB/vehicle application. Arginase activity in ear tissues after 24 hours of exposure to DNCB 
was determined by arginase assay. Means ± SEM, *p<0.05, ns= not significant. 
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Supplementary figure 2.6- Sensitized K14.E7 mice exhibit enhanced ear swelling 
response, arginase-1 mRNA and arginase activity after DNCB challenge. K14.E7 and 
C57BL/6 mice were sensitized topically with 5% of DNCB on the abdomen. Five days later, all 
mice were challenged with 1% of DNCB (left ear) or vehicle (right ear). The ear swelling was 
measured within five day after DNCB challenge (a). Arginase activity in ear tissues harvested 
24 hours after DNCB challenge was assessed by arginase assay (b). Relative gene 
expression of arginase (c) and arginase-2 (d) were determined by real-time PCR in ear 
tissues of C57BL/6 and K14.E7 mice 1 day after DNCB challenge. Means ± SEM, n= 5 mice 
per group, *p<0.05, **p<0.01, *** p<0.001, ns= not significant. 
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Discussion 
 
DNCB triggers a T-cell–independent inflammatory response through the activation of 
the NALP-3 inflammasome in keratinocytes (147), and it has been used to treat HPV-
associated genital warts. Despite its efficacy, this chemical is potentially mutagenic and 
carcinogenic (66). Therefore, we sought to understand the influence of the expression of the 
major oncogenic protein of HPV16, E7, on the inflammatory mechanism induced by DNCB 
using mice transgenic for the E7 protein expressed in keratinocytes. Here, we show that the 
acute response to DNCB in previously unexposed mice is significantly higher in K14.E7 
transgenic mice than in nontransgenic mice. In response to DNCB-induced inflammasome 
activation, keratinocytes have been shown to produce a wide range of proinflammatory 
cytokines including IL-6 and IL-1β (148, 149), which are known to be responsible for the 
recruitment of polymorphonuclear cells (140, 141). We indeed found an increased number of 
inflammatory myeloid cells in the dermis and enhanced mRNA expression levels of IL-6 and 
IL-1β, in DNCB-treated K14E7 transgenic mice, and show further that DNCB-induced IL-1β 
and IL-6 production was greatly enhanced in K14E7 skin when compared with nontransgenic 
skin. We could not detect significant induction of IL-6 in nontransgenic skin. Therefore, we 
hypothesize that this cytokine might be a regulator of inflammatory cell infiltration in K14.E7 
skin and its ear swelling. Premalignant skin of HPV16.E7 transgenic mice is characterized by 
hyperplastic epidermis and infiltration of innate immune cells of myeloid origin. The presence 
of these cells in K14.E7 skin might be responsible for the marked inflammatory response to 
short-term DNCB treatment and inflammasome activation. Interestingly, we were not able to 
detect these responses to DNCB in other transgenic skin including K14.hGh and K5.OVA 
(Supplementary figure 2.2), suggesting that they are unique to K14.E7 mice, a consequence 
of the presence of HPV.E7 oncoprotein in the skin. 
DNCB treatment of K14.E7 mice significantly induced mRNA expression of Th2 
cytokine IL-4 and IL-10, when compared with wild-type mice. This finding is consistent with 
the finding in a mouse model of allergic skin inflammation, in which Th2 cytokines are 
responsible for the amplification and chronicity of allergic skin inflammation (74), and with a 
study in which IL-4-deficient mice displayed an impaired ear swelling response to DNCB 
application (73). Furthermore, we show that DNCB-treated K14.E7 skin exhibited an 
accumulation of CD11b+ myeloid cells, but not of non-myeloid bone marrow–derived cells, 
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which are mainly lymphocytes. Th2 cytokines induce arginase activity in myeloid cells 
including macrophages and dendritic cells (150, 151). Arginase-2 can be expressed by 
macrophages, and it has structural and enzyme characteristics similar to arginase-1 (152), 
but it remained unchanged in K14.E7 skin. Thus, the higher level of arginase activity in 
DNCB-treated K14.E7 mice is mainly contributed by arginase-1, and is promoted possibly by 
higher levels of Th2 cytokines and by accumulation of myeloid cells. 
One predicted source of enhanced Th2 cytokine production in DNCB-treated K14E7 
skin would be Th2 CD4+ lymphocytes. Indeed, K14E7 skin has a large number of 
CD4+ lymphocytes (139). However, we demonstrate here that the induction of arginase-1 and 
enhanced ear swelling response of K14.E7 skin are independent of lymphocytes. To confirm 
that, we performed experiments in sensitized animals and showed that following DNCB 
treatment, sensitized K14.E7 skins also displayed significantly enhanced ear swelling, 
arginase-1 mRNA and arginase activity production compared to non-transgenic skin as 
observed in non-sensitized mice (Supplementary figure 2.6). Th2 cytokines, which induce 
arginase-1 expression and hyperinflammatory response in DNCB-treated K14.E7, might 
therefore be derived from innate immune cells (153, 154) or epithelial cells (155). We also 
detected the induction of prostaglandin E2 synthase in DNCB-treated K14.E7 skin. Our data 
are consistent with a previous study that HPV16.E7 oncoprotein induced cyclooxygenase-2 
transcription and prostaglandin E2 synthase production (156). Furthermore, the 
cyclooxygenase 2–Pteg2s synthase axis has been shown to induce arginase-1 in myeloid 
cells in a tumor environment (157). However, further studies are needed to address the 
induction mechanism of arginase-1 in DNCB-treated K14.E7 skin. 
Cells producing arginase-1 in K14.E7 skin were positive for F4/80 and Ly6C antigen, 
and express Gr1 at the intermediate level. This population has been defined as monocytic 
myeloid suppressive cells or inflammatory monocytes, which appear to adopt an immune 
stimulatory or suppressive function depending on the local environment (158). Indeed, 
CD11b+Gr1+ cells during the early phase of polymicrobial sepsis exhibit proinflammatory 
phenotypes, whereas this cell population becomes immature and immune suppressive in the 
late phase (159). Apart from IL-4 and IL-10, the induction of other Th2 cytokines including IL-5 
and IL-13 could not be detected in DNCB-treated K14.E7 skin (Supplementary figure 2.3).  
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To understand the role of arginase in the hyperinflammation in K14.E7 skin, we used 
the compound nor-NOHA, which efficiently suppresses arginase-1 and arginase-2 activity 
in in vitro and in vivo studies (145, 146). Nor-NOHA abrogates the function of arginase by 
modifying the structure of the enzyme, and it does not affect the transcription of the arginase 
gene, consistent with an unaltered arginase mRNA level (160). Arginase inhibitor treatment 
decreased the arginase activity and the level of leukocyte infiltrate and ear swelling in DNCB-
treated K14.E7 mice. This suggests that enhanced arginase activity is critically required for 
the strong and sustained inflammatory response and that arginase inhibitor alleviates DNCB-
induced inflammation by decreasing the recruitment of leukocytes in the skin. Arginase 
efficiently competes with inducible nitric oxide synthase for the common substrate, l-arginine, 
leading to the inhibition of inducible nitric oxide synthase expression and NO production. As 
endothelium-derived NO is reported to suppress the expression of adhesion molecules such 
as vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 (123), limiting of 
NO bioavailability through arginase results in enhanced vascular inflammation (124). In a 
mouse model of atherogenesis, arginase-2 but not arginase-1 enhances monocyte adhesion 
to endothelial cells and triggers the production of proinflammatory cytokines through 
mitochondrial reactive oxygen species (126). Liu et al. (2013) show that infiltrating myeloid 
cells produce arginase-1, which promotes angiogenesis and further recruitment of monocytes 
in a laser-induced injury murine model (127). 
Taken together, our findings demonstrate that HPV16.E7 oncoprotein–expressing skin 
develops a hyperinflammatory response to DNCB via an arginase-1-dependent mechanism. 
These findings provide insights into the proinflammatory role of arginase-1 in HPV16.E7-
expressing skin in response to immunostimulation by DNCB. 
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Materials and Methods 
 
Mice 
 
K14.HPV16E7 (K14.E7) mice were generated from inbred strain C57BL/6 (161). 
K14.E7, K14.HgH, and Rag−/−, all on a C57BL/6 background, were purchased from Animal 
Resources Center (Perth, Australia). K5.mOVA mice on a C57BL/6 background were kindly 
provided by H. Azukizawa (162). Rag−/− × E7 mice were generated by crossing male K14.E7 
with female Rag1−/− knockout C57BL/6 mice; heterozygous K14E7 mice were crossed and 
then backcrossed with homozygous Rag1−/− mice to an F2 generation (161). All mice were 
maintained under specific pathogen-free conditions at Princess Alexandra Hospital Biological 
Research Facility. Experimental mice were sex-matched and used at 6–9 weeks of age. All 
animal procedures complied with guidelines approved by the University of Queensland 
Animal Ethics Committee. 
 
DNCB treatment 
 
DNCB (Sigma, Sydney, New South Wales, Australia) was dissolved in vehicle 
(acetone: olive oil (4:1)) immediately before use. Six- to nine-week-old mice were treated with 
20 μl of 1% DNCB or vehicle on the left ear and right ear, respectively. After 24 hours, the ear 
tissues were collected for mRNA and protein analysis. Ear thickness was measured by using 
the digital caliper, and change in ear swelling was determined by calculating the mean 
increase in ear thickness compared with untreated ears. 
 
Histological analysis 
 
Ear tissues were fixed using 4% paraformaldehyde. Tissues were embedded in 
paraffin and 7-μm sections were prepared and stained with hematoxylin and eosin. Immune 
cell infiltration was evaluated by light microscopy and quantified by using the Nis-elements Br 
3.2 software (Nikon Instruments, New York, NY). 
 
Real-time PCR 
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RNA was isolated from homogenized tissues by using the RNaeasy Mini kit (Qiagen, 
Melbourne, Victoria, Australia). RNA extracts were quantified using absorption of light at 260 
and 280 nm (A260/280). Details of the procedures and primers used for the quantitative real-
time PCR are described in Supplementary Methods online. 
 
Arginase activity 
 
Arginase activity was measured by colorimetric determination of urea formed from l-
arginine, as previously described (163). Details of the procedures are desbribed 
in Supplementary Methods.  
 
Flow cytometry and cell sorting 
Flow cytometry staining was performed as previously described (44). Details of flow 
cytometry and cell sorting are described in Supplementary Methods  
 
Statistical analysis 
 
Each data point represents the mean±SEM and is representative of two independent 
experiments with at least four mice per group. 
Prism (Graph pad Software, La Jolla, CA) was used for graphs and statistical analysis:  
*P<0.05;**P<0.01; ***P<<0.001; ****P<0.0001. Multiple comparisons of ear swelling data 
were derived by two-way analysis of variance. For other data, statistically significantly 
differences between groups were analyzed by non-parametric Mann–Whitney-Wilcoxon test. 
 
Inhibition of arginase activity 
 
 Mice were injected i.p. with either 500 µg of Nor-NOHA/500 μl PBS or 500 μl of PBS 
alone one day prior to DNCB treatment. The treatment was repeated daily for 5 consecutive 
days. Nor-NOHA is a synthetic analog of NOHA, an intermediate of L-arginase pathway. The 
inhibitor specifically interacts with the manganese-cluster of the enzyme active site of 
arginase and does not function as a substrate or as an inhibitor for other factors (164). There 
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is extensive literature confirming specificity of nor-NOHA as a specific inhibitor of arginase in-
vitro (145) and in-vivo (146). 
 
Arginase activity 
 
Briefly, ear tissues were homogenized in PBS buffer containing protease inhibitor 
cocktail (Roche Diagnostics, New South Wales, Australia), centrifuged and supernatants 
collected. Protein concentration was determined by using bicinchoninic acid (BCA) assay 
(Thermo Fisher Scientific, Victoria, Australia). 50 µl of tissue lysate was preactivated by 
adding 50 µl of 10 mM MnCl2/50 mM Tris/HCl at pH 7.5 and heating for 10 min at 56
oC. 50 µl 
of 0.5 M L-arginine substrate (pH 9.5) was added to the samples and further incubated at 
37oC for 120 min. The reaction was stopped by adding 400 µl of H2SO4: H3PO4: H2O (1:3:7, 
v/v/v). After adding 25 µl of 9% 1-phenyl-1,2-propanedione-2-oxime, the samples were then 
boiled for 45 min at 100oC. Urea concentration was determined using a spectrophotometer at 
540 nm. Using a standard curve, arginase activity was calculated as units/ml/100 mg protein 
lysate. One unit of Arginase is the amount of enzyme that will convert 1.0 mmole of L-arginine 
to ornithine and urea per minute at pH 9.5 and 37 °C (165). 
 
Real-time PCR reaction 
 
For cDNA synthesis, 500 ng of total RNA was reverse transcribed in 20 µl reaction 
containing 5 mM MgCl2; 1.6 mM dNTP mix, 2.5 mM oligo-dT, 1 µl of MuLv reverse 
transcriptase 5000U (Applied Biosystems, Victoria, Australia) and 10 units of RNaseOUT 
(Invitrogen, Victoria, Australia) at 42oC for 60 min. The reactions were heated at 70oC for 15 
min to inactivate reverse transcriptase enzyme. cDNA product was diluted at 1:4 and 2.5 µl 
was subjected to real-time PCR reaction using SYBR TAKA kit (Scientifix, Victoria, Australia) 
and primers (Integrated DNA Technologies, Iowa, United States) listed in supplementary table 
1. The relative expression of arginase-1 and arginase-2 was determined by normalizing 
against the house keeping gene encoded ribosomal protein RPL32.  
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Supplementary Table 1- Primers used for real time PCR determinations 
Gene Forward 5’ – 3’ Reverse 3’ – 5’ 
Arginase-1 AAGAATGGAAGAGTCAGTGTGG GGGAGTGTTGATGTCAGTGTG 
Arginase-2 GATCTCTGTGTCATCTGGGTTG AATCCTGGCAGTTGTGGTAC 
IL-4 CGAATGTACCAGGAGCCATATC TCTCTGTGGTGTTCTTCGTTG 
IL-10 GGAGTCGGTTAGCAGTATGTTG AGCCGGGAAGACAATAACTG 
IFN-γ GAACTGGCAAAAGGATGGTGA TGTGGGTTGTTGACCTCAAAC 
Ptge2s CAGTATTACAGGAGTGACCCAG AAATGTATCCAGGCGATCAGAG 
IL-6 CAAAGCCAGAGTCCTTCAGAG GTCCTTAGCCACTCCTTCTG 
IL-1β GTTGATTCAAGGGGACATTA GTTGATTCAAGGGGACATTA 
 
Flow cytometry and cell sorting 
 
Single cell suspensions were prepared from ear tissues by using 
collagenaseD/dispase (Roche Diagnostics) and grinding through a 70µm cell strainer. After 
adding Fcγ receptor block (Fcγ III/II receptor; BD Biosciences, Auckland, New Zealand, 1/50) 
and incubating on ice for 10 min, cells were stained with live/dead aqua dyes (Live/Dead 
fixable aqua dead cell stain kit, Invitrogen, 1/1000) and antibodies specific for the following 
markers for 30 min at 4˚C: CD45.2-PE-Cy7 (BD Biosciences, 1/200); CD11b-PE (BD 
Biosciences, 1/100), F4/80-FITC (eBioscience, San Diego, United States 1/100), and 
Gr1(Ly6G/Ly6C)-APC (eBioscience, 1/200), Ly6G-Alexa 700 (Biolegend, San Diego, United 
State, 1/200), Ly6C-APC.Cy7 (Biolegend, 1/100). Stained cells were acquired on a LSIR II or 
FACSCanto flow cytometer (BD Biosciences) and analyzed using Kaluza software (version 
1.2, Beckman Coulter, New South Wales, Australia).   
Chapter 2 
 
 58 
For cell sorting, ear tissues were processed as described above. Cells were stained in FACS 
staining buffer with anti–CD11b-PE, anti–CD45.2-PeCy7, anti-F4/80-FITC and anti-Gr1 
(Ly6G/Ly6C)-APC. Viable CD45.2+CD11b-; CD45.2+CD11b+; and 5 different subsets of 
CD45.2+CD11b+ cells (Gr1-; F4/80hiGr1int; F4/80lowGr1int; F4/80hiGr1hi; F4/80-Gr1hi) were 
sorted under BSL2 conditions on MoFlo Astrios cell sorter (BD Biosciences).  
RNA from sorted cells was isolated by the RNAzol method (Sigma).  
Total protein was isolated from sorted cells by resuspending cells in 50 μl of lysis buffer 
(20 mM Tris, 100 mM NaCl, 1 mM EDTA, 0.5% Triton X100) and incubating for 20 min. After 
centrifugation at 13,000 g at 4oC for 20 min, the supernatant was collected for protein 
quantification (BCA) and arginase assay. 
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2.3 Additional data not described in the article 1 
 
Arginase enhances nitric oxide (NO) production in DNCB-treated K14.E7 skin 
 
As mentioned in 1.6, arginase-1 efficiently competes with iNOS for the common 
substrate L-arginine, leading to the inhibition of iNOS expression and NO production. 
Since NO has been reported to play an important role during cutaneous inflammation 
(166), we examined a possible contribution of arginase to the regulation of iNOS mRNA 
expression and NO production in DNCB-treated C57BL/6 and K14.E7 skin. Compared to 
non-detectable values in wild-type skin, the levels of iNOS mRNA expression and NO 
production were significantly induced in K14.E7 skin after DNCB application (Figure 2.6a 
and b). Unexpectedly, we found that blockade of arginase activity resulted in a trend 
towards decreased iNOS mRNA expression (Figure 2.6a) and a significant reduction of 
NO production in DNCB-treated K14.E7 skin (Figure 2.6b). Thus, these data suggested 
that DNCB treatment of K14.E7 mice induced NO production in the skin and that arginase 
might promote, rather than suppress, NO production. Given that the inhibitor used in this 
study specifically targeted arginase (167), this paradox can be explained by the impact of 
arginase on the recruitment of innate immune cells, including NO-producing cells rather 
than the competition for L-arginine substrate. Indeed, NO can be produced by many innate 
immune cell types, including macrophages, neutrophils, DCs (168) raising the possibility 
that arginase-1 might indirectly promote iNOS gene expression and NO production by 
enhancing the infiltration of NO-producing cells. Taken together, stimulation of NO-
producing cell infiltration might be a potent mechanism by which arginase drives the 
DNCB-induced hyperinflammation in K14.E7 skin. This hypothesis is supported by a 
previous study showing that NO-derived neutrophils is involved in stimulating further 
neutrophil accumulation into the skin, thereby promoting zymosan-induced cutaneous 
inflammation (166).  
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Figure 2.6- Suppression of arginase attenuates NO production in DNCB-treated 
K14.E7 skin. K14.E7 mice were injected with 500 μg of arginase inhibitor, nor-NOHA or 
saline buffer (PBS) 1 day before and 1 hour before DNCB treatment. Ear skin tissue was 
harvested for RNA isolation or skin explant culture. (a) iNOS mRNA expression in 
C57BL/6 and nor-NOHA or PBS-treated K14.E7 skins at day 1 following DNCB 
application, determined by real-time PCR. (b) NO production in the supernatants of these 
skin explants measured by the Griess reaction. Data are presented as means±SEM. UD, 
undetermined; NS, not significant. *, P<0.05. 
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2.4 Supplementary methods 
 
iNOS gene expression   
 
Relative expression of iNOS mRNA was determined by real-time PCR as described in 
materials and method in 2.1. The sequence of forward and reverse iNOS primers were: 5’ 
GCAAACATCACATTCAGATCCC 3’ and 5’ TCAGCCTCATGGTAAACACG 3’, respectively.  
 
Griess assay-NO production 
 
Nitrite concentration as a reflection of NO production was determined by the Griess 
reaction as previously described (169). Briefly, 24 hours after DNCB application, ears were 
excised, split into halves and placed dermis side down on 2 ml of complete DMEM (10% (v/v) 
fetal bovine serum, 1 mM penicillin/streptomycin/glutamine, 1mM sodium pyruvate and 10 
mM HEPES (Gibco)) at 37oC, 5% CO2. After 24 hours, 100 μl of skin explant supernatant and 
or NaNO2 standards were incubated in duplicate with 100µl Griess reagent (0.5% 
sulfanilamide, 0.05% naphthyldiamine dihydrochloride (Sigma) in 5% H3PO4) for 10 min. The 
plates were read at 550 nm. 
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2.5 Conclusion 
 
In this chapter, I have shown that DNCB application to skin expressing HPV16.E7 as a 
transgene results in an acute hyperinflammatory response, which is not seen in 
nontransgenic control animals. The E7-associated hyperinflammation is manifested by the 
induction of Th2 cytokines and recruitment of CD11b+Gr1intF4/80+Ly6ChiLy6Glow myeloid cells, 
producing arginase-1. Consequently, arginase-1 mediates DNCB-induced acute inflammation 
by enhancing the recruitment of more leukocytes and production of NO.  
However, many questions remain unanswered. First of all, as I have found that the 
regulation of arginase-1 and DNCB-induced hyperinflammation in K14.E7 skin are 
independent of T and B cell function, it would be interesting to address whether Th2 cytokines 
or other cytokines released from innate immune cells are involved in the induction of 
arginase-1. Secondly, how arginase and its inducers mediate DNCB-induced 
hyperinflammation in K14.E7 skin requires further study. Furthermore, whether innate 
immune activation mediated by DNCB can break the tolerance of HPV16.E7 oncoprotein. 
Lastly, is the induction of arginase in DNCB-induced hyperinflammation dependent on the 
expression of HPV16.E7 protein in the skin? 
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IL-17A Mediates Arginase-1 induction and DNCB-
induced inflammation in HPV16.E7 expressing skin 
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3.1 Foreword 
 
Data shown in chapter 2 demonstrated the significant contribution of arginase-1 to the 
DNCB-induced acute hyperinflammation in HPV16.E7 expressing skin. However, the 
molecular basis regulating arginase-1 expression in association with HPV16.E7 oncoprotein 
has not been previously elucidated. It has been well established that the regulation of 
arginase-1 is dependent on the cytokine milieu in which arginase-1 is primarily induced in 
response to Th2 cytokines. In addition, recent studies have shown that IL-17A is implicated in 
the induction of arginase-1 by myeloid cells in epithelial inflammatory diseases including 
asthma and colitis. This chapter therefore aims to investigate the possible involvement of 
these cytokines in the regulation of arginase-1 and development of hyprerinflammatory 
response to DNCB. The study has been submitted to Journal of Immunology and formatted 
as requested by the journal. 
Furthermore, it has been reported that immunization therapy with HPV16.E7 
oncoprotein alone is not sufficient to induce rejection of K14.E7 skin graft. This chapter also 
addressed whether DNCB-induced inflammation combined with E7 specific vaccination 
therapy enables the rejection of K14.E7 skin graft.   
 
. 
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3.2 Article 2 
 
Interleukin-17A Promotes Arginase-1 Production And DNCB-Induced Acute 
Hyperinflammation In Human Papillomavirus E7 Oncoprotein Expressing Skin1,2 
 
Running title: IL-17A in DNCB-induced hyperinflammation in Human Papillomavirus E7 
oncoprotein expressing skin 
Tran L.S.*,  Mittal D†, Mattarollo S.R.*, Frazer I.H.* 
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Abstract 
Human Papillomaviruses (HPVs) have evoked numerous mechanisms to subvert 
host innate immunity and establish a local immunosuppressive environment to facilitate 
persistent virus infection. Topical application of 2,4-dinitrochlorobenzene (DNCB) was 
speculated to overcome this immune-suppressive environment and employed in the 
immunotherapy of HPV-associated lesions.  
We have previously shown that DNCB treatment of skin expressing HPV16.E7 
protein, the major oncogenic protein expressed in HPV-associated premalignant cervical 
epithelium, results in a hyperinflammatory response, with associated induction of Th2 
cytokines and an infiltration of myeloid cells producing arginase-1 that also contributes to 
the hyperinflammation. However, the molecular mechanisms underlying arginase-1 
induction and arginase-mediated hyperinflammation in K14.E7 skin have not been 
elucidated. Here, we show that HPV16.E7 protein expression as a transgene in skin is 
associated with enhanced IL-17A production by macrophages exposed to DNCB. 
Interestingly, induction of arginase by DNCB is not seen in K14.E7 animals unable to 
express IL-17A. Further, blockade of either IL-17A or arginase alleviates DNCB-induced 
hyperinflammation, through reduced recruitment of neutrophils, as a consequence of 
decreased CXCL1 and CXCL5 chemokine production. Thus, our findings suggest that 
increased IL-17A expression by macrophages in E7 expressing skin exposed to DNCB 
promotes arginase-1 induction and contributes directly to the observed hyperinflammation. 
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Introduction 
 
Persistent infection of basal keratinocytes with oncogenic Human papillomavirus 
(HPV), particularly HPV type 16, causes epidermal dysplasia and eventually squamous 
cancers (1). Establishment of HPV persistence is associated with its ability to subvert 
effective innate immunity through the action of two major oncoproteins, E6 and E7 (21). 
 K14.E7 transgenic mice in which a single viral HPV type 16 E7 oncoprotein is 
expressed within the basal keratinocytes under the control of the keratin 14 transcriptional 
promoter, have been extensively employed as a model of HPV-associated premalignancy 
to study the mechanisms of immune-suppression mediated by this viral oncoprotein (13). 
Indeed, previous investigations using this model have revealed that HPV16.E7 
oncoprotein induces a localized immune suppressive environment and that successful 
therapies need to circumvent or disrupt this environment (44, 54).  
Stimulation of innate immunity by topical application of DNCB, a contact 
hypersensitizer, was recognized as a promising therapy for resistant warts caused by HPV 
(65). The effectiveness of this approach is ascribed to the activation of innate immune 
defense mechanisms through a strong cutaneous inflammation induced by DNCB (69). 
Although clinical application of DNCB has been discouraged due to its potent mutagenic, 
genotoxic and carcinogenic hazards (66), we hypothesised that understanding how DNCB-
induced acute inflammation can alter the local immune suppressive environment 
generated by HPV16.E7 oncoprotein might lead to better treatment options for HPV 
persistently infected patients. Our recent study showed that treatment of K14.E7 skin with 
DNCB causes a hyperinflammatory response which is associated with enhanced 
recruitment of myeloid cells producing arginase-1, and that arginase-1 is required for the 
development of DNCB-induced hyperinflammation (170). However, the molecular basic of 
signaling axis regulating arginase-1 induction, as well as how arginase-1 regulates the 
hyperinflammation in K14.E7 skin, have not been elucidated.   
Th2 cytokines including IL-4  and IL-13 drive the induction of arginase-1 in myeloid 
cells through STAT6 transcriptional factor (171, 172). In a murine asthma model, Th2 
cytokines induced arginase-1 and allergic airway inflammation (74). In addition to Th2 
cytokines, IL-17A, an important cytokine of innate immunity, has also been shown to 
induce arginase-1 production in inflammatory macrophages in a model of Leishmania 
amazonensis  infection (173), in vascular inflammation (174) and in a tumor environment 
(175).  
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Although IL-17A is primarily produced by T helper 17 cells and other lymphocyte 
subsets (γδ T cells, invariant natural killer T cells), recent studies have reported that innate 
immune cells including neutrophils (176) and macrophages (177) are important cellular 
sources of IL-17A. IL-17A, which signals through a receptor complex composed of IL-
17RA /IL-17RC, mediates skin lesions through induction of chemokines and recruitment of 
innate immune cells (178). 
Since regulation of arginase is dependent on a cytokine milieu, the present study 
aimed to investigate the involvement of these cytokines in the induction of arginase-1 and 
the enhanced inflammation in K14.E7 skin. Here, we show that suppression of IL-17A and 
not Th2 cytokines caused a significant reduction in the production of arginase-1 in K14.E7 
skin exposed to DNCB, indicating involvement of IL-17A in arginase-1-mediated 
hyperinflammation in K14.E7 skin.  
In addition, we show that IL-17A is induced by CD11b+F4/80+ macrophages in the 
absence of lymphocytes and that IL-17A together with its down-stream mediator, arginase-
1, participates in ongoing DNCB-induced hyperinflammation in K14.E7 skin through 
enhanced recruitment of neutrophils. Taken together, our findings demonstrate that IL-17A 
promotes DNCB-induced hyperinflammatory response in HPV16.E7 skin, concomitant with 
the induction of arginase activity.  
Chapter 3 
 
 69 
Materials and Methods 
 
Mice 
 
HPV16.E7 transgenic C57BL/6 mice (designated K14.E7) which express HPV type 
16 E7 oncoprotein under control of keratin 14 promoter were generated from inbreed 
strain, C57BL/6 mice (161). Rag1-/- and IL-17A-/- mice were obtained from the Animal 
Resources Center (Perth, Australia) and Professor Helen Thomas (The University of 
Melbourne), respectively. E7.Rag-/- and E7.IL17-/- were generated by crossing male 
K14.E7 mice with female Rag1-/- or IL17-/- knockout (KO) C57BL/6 mice, heterozygous 
K14E7 mice were crossed and then backcrossed with homozygous Rag1-/- or IL17-/-  mice 
to an F2 generation (161). K14.hGH mice were purchased from the Animal Resources 
Center (Perth, Australia). All mice, on C57BL/6 background, were maintained under 
specific pathogen-free conditions at Translational Research Institute-Biological Research 
Facility. Experimental mice were sex-matched and used at 6-9 week of age.  All animal 
procedures complied with guidelines approved by the University of Queensland Animal 
Ethics Committee (AEC#367/13). 
 
Media and Reagents 
 
Complete medium was DMEM supplemented with 10% heat inactivated fetal calf 
serum (FCS), 1% penicillin/streptomycin, 1% L-glutamine, 1% Sodium Pyruvate, 1% 
HEPES (Gibco, Victoria, Australia). 
Neutralizing monoclonal antibodies (Mabs) against IL-4 (Rat IgG1, clone 11B11)  
and IL-10 (Rat IgG1, clone JES5-2A5) and matched-isotype control Mab (Rat IgG1, clone 
eBRG1) were purchased from eBioscience (California, USA). Mab, rat IgG1, against 
murine IL-17A (LA426), and control isotype-matched rat mAb (2405001) were obtained 
from Lilly Research Laboratories (Illinois, USA). 
Mouse IL-17A (homodimer) enzyme-linked immunosorbent assay Ready-SET-Go 
kits (ELISA) with sensitivity limit of 4 pg/ml were purchased from eBioscience.  
 
DNCB treatment 
 
2,4-dinitrochlorobenzene (Sigma, New South Wales, Australia) was dissolved in 
acetone: olive oil (4:1) immediately prior to use. For IL-17A neutralization in vivo, six- to 
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nine-week-old mice were intraperitoneally administered at a dose of 10 mg/kg of anti-IL-
17A blocking antibody or matched-isotype control antibody. After 24 hours, the treatment 
was repeated 30 min before applying 20 µl of 1% or 10% (m/v) DNCB on the left ear and 
20 µl of vehicle (acetone:olive oil 4:1) on the right ear. The ear tissues were harvested for 
mRNA and protein analysis 24 hours following DNCB treatment. Ear thickness was 
measured within 5 consecutive days by using the digital caliper and change in ear swelling 
was determined by calculating the mean increase in ear thickness compared to untreated 
ears.  
For arginase suppression, mice were injected with 500 µg of arginase inhibitor, nor-
NOHA (Cayman, MI, USA) or saline buffer one day prior to DNCB treatment and daily for 5 
days 
 
Skin explant culture 
 
 Four hours after DNCB exposure, ear skin was excised and split into dorsal and 
ventral halves and each ear half was placed dermis side down on 2 ml of complete DMEM, 
24-well tissue culture plates at 37oC, 5% CO2. To reduce the effect of cell-death related 
release of cytokines and danger signals, after 1 hour, the culture medium was exchanged 
with 2 ml of fresh complete DMEM. For in vitro cytokine neutralization, culture medium was 
supplemented with 10 ng/ml of anti-IL-4, anti-IL-10 or anti-IL-17A neutralizing mabs and 
matched Rat IgG1 isotype control mab. Ear skin explant supernatant was collected after 
20 hours and used for BMDM stimulation or cytokine production analysis by ELISA.  
 
Preparation and cultivation of BMDM 
 
Bone marrow cells were flushed from femurs and tibias of C57BL/6 mice and 
cultivated in complete DMEM medium supplemented with 20% L-cell conditioned medium 
(kindly provided by Dr. Antje Blumenthal) and cultured at 37oC, 5% CO2. 5 ml of fresh 
medium was added to culture every 2 days. After 6 days, BMDM cells were harvested and 
seeded in complete DMEM medium at a concentration of 5x105 cells/ml, then allowed to 
recover for two hours before performing in vitro stimulation. Monoclonal antibodies against 
IL-4, IL-10 or IL-17A and matched-isotype control antibodies were added to culture 
medium 30 minutes before stimulating BMDM cells with 20% skin explant supernatant. 
After 24 hours, BMDM cells were harvested by using cold 0.05% EDTA in PBS. Total 
protein was isolated from sorted cells by resuspending cells in 50 μl of lysis buffer 
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containing 20 mM Tris, 100 mM NaCl, 1 mM EDTA, 0.5% Triton X100, EDTA- 
Minicomplete protease inhibitor (Roche diagnostics, New South Wales, Australia) and 
incubating for 30 min. After centrifugating at 13,000 g at 4oC for 20 min, the supernatant 
was collected for protein quantification determined by using PierceTM bicinchoninic acid 
(BCA) protein assay (Thermoscientific, Illinois, USA) and then 100 μg of protein lyaste was 
used to determine arginase activity.  
 
Arginase enzymatic assay 
 
Arginase activity was measured by colorimetric determination of urea formed from 
L-arginine as previously described (163).  
 
IL-17A ELISA 
 
IL-17A production in skin explant supernatant was determined following the 
manufacturer’s instructions. IL-17A concentration in supernatant was normalized to weight 
of the skin explant and shown as pg/mg tissue. 
 
Realtime-PCR 
 
Table 3.1- Primer sequences 
Gene Forward 5’ – 3’ Reverse 3’ – 5’ 
RPL32 GGTGAAGCCCAAGATCGTC TTGGGATTGGTGACTCTGATG 
Arginase-1 AAGAATGGAAGAGTCAGTGTGG GGGAGTGTTGATGTCAGTGTG 
Arginase-2 GATCTCTGTGTCATCTGGGTTG AATCCTGGCAGTTGTGGTAC 
IL-4 CGAATGTACCAGGAGCCATATC TCTCTGTGGTGTTCTTCGTTG 
IL-10 GGAGTCGGTTAGCAGTATGTTG AGCCGGGAAGACAATAACTG 
IL-17A TCCAGAATGTGAAGGTCAACC TATCAGGGTCTTCATTGCGG 
CXCL1 AACCGAAGTCATAGCCACAC CAGACGGTGCCATCAGAG 
CXCL2 GAAGTCATAGCCACTCTCAAGG CTTCCGTTGAGGGACAGC 
CXCL5 GTTCCATCTCGCCATTCATG TTAAGCAAACACAACGCAGC 
 
Total RNA was isolated from homogenized tissues by using RNaeasy Mini kit 
(Qiagen, Victoria, Australia). RNA extracts were quantified using absorption of light at 260 
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and 280 nm (A260/280). For cDNA synthesis, 500 ng of total RNA was reverse transcribed 
in 20 µl reaction containing 5 mM MgCl2; 1.6 mM dNTP mix, 2.5 mM oligo-dT, 1 µl of MuLv 
reverse transcriptase 5000U (Applied Biosystems, Victoria, Australia) and 10 units of 
RNaseOUT (Invitrogen, Victoria, Australia) at 42oC for 60 min. The reactions were heated 
at 70oC for 15 min to inactivate reverse transcriptase enzyme. cDNA product was diluted 
at 1:4 and 2.5 µl was subjected to real-time PCR reaction using SYBR TAKA kit (Scientifix, 
Victoria, Australia) and primers (Integrated DNA Technologies, Iowa, United States) listed 
in table 2.1. The relative expression was determined by normalizing against the house 
keeping gene RPL32 (L32 ribosomal protein gene).  
 
Flow cytometric analysis 
 
Single cell suspensions were prepared by incubating minced ear skin tissue in 2 
mg/ml dispase (Roche Diagnostics) for 1 hour and 0.3 mg/ml collagenaseD (Roche 
Diagnostics) for 30 min and grinding through a 70µm cell strainer. After adding Fcγ 
receptor block (Fcγ III/II receptor; BD Biosciences, Auckland, New Zealand, 1/50) and 
incubating on ice for 10 min, cells were stained with live/dead aqua dyes (Live/Dead 
fixable aqua dead cell stain kit, Invitrogen, 1/1000) and antibodies specific for the following 
surface markers for 30 min at 4˚C: CD45.2-PerCP5.5 (eBioscience, clone 30-F11) ; 
CD11b-Pacific Blue (eBioscience, clone M1/70) , F4/80-FITC (eBioscience, clone BM8), 
Gr1(Ly6G/Ly6C)-APC (eBioscience, clone RB6-8C5)), MHC-II-APC.Cy7 (Biolegend, clone 
M5/114.15,2) , CD11c-PE.Cy7 (BD Pharmingen, clone HL3)  and CD3-PE (eBioscience, 
clone 17A2). Cells were fixed and permeabilized the BD Biosciences Cytofix/Cytoperm kit 
(BD Pharmingen) according to the manufacturer's instructions before stained 
intracellularly with mab against IL-17A or matched isotype control antibody (eBiosciences, 
1/100) for 45 min. Flow-Count fluorospheres (Beckman Coulter) for absolute cell 
counting was added to stained cells before acquiring on a LSR fortessa II cytometer (BD 
Biosciences). Data was analyzed using Kaluza software (version 1.2, Beckman Coulter, 
New South Wales, Australia).  
 
Histological analysis 
 
Ear tissues were fixed in 4 % paraformaldehyde for 24 hours. Tissues were 
embedded in paraffin and 7 µm sections were prepared and stained with Hematoxylin and 
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Eosin. Immune cell infiltration was evaluated by light microscopy using Nis-elements Br 
3.2 software (Nikon Instruments Inc., New York, United States).  
Paraffin sections were dewaxed and rehydrated through xylol and descending 
graded alcohols to Tris buffered saline (TBS) pH 7.6. Endogenous peroxidase activity is 
blocked by incubating the sections in 2.0% hydrogen peroxide in TBS for 10 minutes. After 
rinsing slides in distilled water, sections were transferred to Biocare Medical Diva retrieval 
buffer pH and subjected to 15 minutes heat antigen retrieval at 105OC using the Biocare 
Medical decloaking chamber. Samples were allowed to cool down for 20 min and washed 
three times in TBS before adding anti-mouse F4/80 (abcam, 1/350), was applied for 90 
minutes at room temperature. Sections are washed in TBS before adding secondary 
antibody, Rat-on-Mouse HRP Polymer Kit (Biocare Medical, United States, CA). Colour is 
developed in DAB for 5 minutes and sections were lightly counterstained in Mayers’ 
haematoxylin, then dehydrated through ascending graded alcohols, cleared in xylene, and 
mounted using DePeX. 
 
Statistical Analysis 
 
Data represents the mean ± SEM and are representative of two independent 
experiments with at least 4 mice per group. Prism (Graph pad Software, California, USA) 
was used for graphs and statistical analysis: *; p<0.05; **; p<0.01; ***, p<0.001; **** 
p<0.0001.  Multiple comparisons of ear swelling data were derived by two-way ANOVA. 
For other data, statistically significantly differences between groups were analysed by non-
parametric Mann-Whitney-Wilcoxon test.   
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Results 
 
DNCB-induced IL-17A, but not IL-4 or IL-10, in K14.E7 skin promotes 
macrophage arginase production 
 
We have previously shown that DNCB treatment of skin expressing the E7 protein 
of HPV.16 as a transgene induces hyperinflammation when compared with similar 
treatment of non-transgenic skin, and that this is associated with the induction of IL-4 and 
IL-10. These cytokines have been described as potent inducers of arginase-1 in 
monocytes/macrophages, so we assessed the link between each of these cytokines and 
arginase-1 production in DNCB-treated K14.E7 skin, using an in-vitro skin explant model. 
BMDM were cultured in supernatants harvested from explant cultures of vehicle or DNCB-
treated skin from C57BL/6, Rag-/-, K14.E7 or E7.Rag-/- mice. BMDM cells exposed to 
supernatant from DNCB-treated K14.E7 or E7.Rag-/- skin explants expressed more 
arginase activity than those exposed to supernatant from vehicle-treated skin explants. By 
contrast, there was no change in arginase activity when BMDM cells were stimulated with 
supernatants from DNCB-treated wild-type C57BL/6 and Rag-/- skin explants (Figure 3.1a). 
These observations confirmed in-vitro our previous ex-vivo observation that DNCB 
treatment of K14.E7 skin leads to enhanced arginase activity in inflammatory 
macrophages, by a mechanism independent of T- and B-lymphocytes (Figure 3.1a).  
We next tested whether IL-4 or IL-10 released by DNCB-treated K14.E7 ear skin is 
involved in the induction of arginase-1 in BMDM, by exposing the BMDM cultures to anti-
IL-4 and anti-IL-10 neutralizing antibodies. Neutralization of IL-4 and IL-10 did not change 
the level of arginase activity in BMDM stimulated with supernatant from DNCB-treated 
K14.E7 skin explant (Figure 3.1b), demonstrating that IL-4 and IL-10 were not necessary 
for the enhanced arginase activity in DNCB-treated K14.E7 skin. 
Since IL-17A has been shown to induce arginase-1 expression by macrophages in 
recent studies (174, 175), we next investigated whether IL-17A played a role in the 
induction of arginase in our model. Depletion of IL-17A with neutralizing antibody, in 
contrast to depletion of IL-10 and IL4, significantly reduced the observed level of arginase 
activity (Figure 3.1b). In support of this observation, BMDM cells cultured in supernatant 
from skin explants from DNCB-treated E7.IL17-/- animals produced less arginase activity 
than those cultured in supernatants from E7.IL17+/- or from K14.E7 skin explants (Figure 
3.1c). 
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 To further confirm a key role for IL-17A in the enhancement of arginase production 
in response to DNCB, we assessed the in-vivo production of arginase in K14.E7 skin and 
E7.IL17-/- skin after DNCB application. Consistent with our in-vitro data, E7.IL17-/- mouse 
skin treated with DNCB demonstrated significantly less arginase activity, and arginase-1 
transcription, than K14.E7 mouse skin (Figure 3.2a and 3.2b). Arginase-2 mRNA 
transcription was reduced to a much lesser extent (Figure 3.2c). Thus, IL-17A contributes 
to the induction of arginase-1 mRNA expression and arginase activity not only in BMDM 
cells in-vitro but also in K14.E7 skin following DNCB application.  
IL-17A has been suggested to mediate recruitment of inflammatory macrophages 
(179). Therefore, we investigated whether IL-17A mediated the induction of arginase-1 in 
DNCB-treated K14.E7 skin by enhancing recruitment of the CD11b+-Gr1intF4/80+ subset of 
macrophages, which we previously showed to be the main cell population producing 
arginase-1 in DNCB-treated K14.E7 skin. The expected extensive infiltrate of F4/80+ cells 
in K14.E7 skin in response to DNCB application, was much reduced in DNCB-treated 
E7.IL17-/- skin, demonstrating that IL-17A enhances recruitment of F4/80+ cells in K14.E7 
skin in response to DNCB (Figure 3.2d). Consistent with this observation, flow cytometric 
analysis showed significantly lower numbers of CD11b+F4/80+Gr1int cells in DNCB-treated 
E7.IL17-/- skin compared to K14.E7 skin (Figure 3.2e).  
Taking these findings together, we conclude that IL-17A, by increasing the number 
of CD11b+F4/80+Gr1int macrophages, is responsible for the increased arginase-1 mRNA 
expression and arginase activity in DNCB-treated K14.E7 skin.  
 
IL-17A is specifically induced in DNCB-treated K14.E7 skin in the absence of 
lymphocytes 
 
As IL-17A contributes to the enhanced induction of arginase-1 in DNCB-treated 
K14.E7 mouse skin, we investigated IL-17A expression in wild–type and K14.E7 mouse 
skin.  Following DNCB application, IL-17A gene expression was significantly induced in 
DNCB-treated K14.E7 skin while it remained unchanged in DNCB-treated wild-type skin 
(Figure 3.3a). Additionally, DNCB-treated K14.E7 skin secreted more IL-17A into the skin 
explant supernatant than wild-type skin (Figure 3.3b). Base levels of IL-17A in untreated 
K14.E7 skin were also higher than that in C57BL/6 skin, as reported previously (35). Thus, 
in addition to Th2 cytokines, IL-17A was induced in K14.E7 skin in response to DNCB.  
As we previously reported that hyperinflammatory response in K14.E7 mice 
exposed to DNCB is independent of lymphocyte function, we investigated the production 
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of IL-17A in E7.Rag-/- skin. Interestingly, IL-17A mRNA expression was significantly 
induced by DNCB in E7.Rag-/- skin, although at a lower level than in E7 skin, but not in 
Rag-/- skin (Figure 3.3a). Consistent with this, the level of IL-17A protein released into the 
skin explant supernatants from both Rag-/- and E7.Rag-/- mice was undetectable by ELISA 
(Figure 3.3b), suggesting a significant contribution of lymphocytes to the enhanced IL-17A 
production in DNCB-treated E7 transgenic skin.  
To establish the role of E7 protein in the induction of IL-17A, we examined the 
induction of IL-17A in another K14 transgenic mouse line (K14.hGH) and in C57BL/6 mice, 
treated with a 10-fold higher dose of DNCB to induce ear swelling level comparable to that 
observed in K14.E7 mouse skin exposed to a lower level of DNCB (Figure 3.3c). In both 
the K14.hGH transgenic and the C57BL/6 mouse skin, no production of IL-17A was 
observed. Thus, induction of IL-17A by DNCB is dependent on expression of HPV16.E7 in 
skin. 
Taken together, these data suggested that expression of HPV16.E7 in skin 
facilitates IL-17A induction in both lymphocyte and “non-lymphocyte” immune subsets in 
response to DNCB. 
 
CD11b+F4/80+ macrophages are the major producers of IL-17A in DNCB-
treated K14.E7 skin 
 
Recent studies have reported that in addition to Th17 cells, various myeloid cells 
including neutrophils (176), and macrophages (177) can produce IL-17A under 
inflammatory conditions. Our observation of induction of IL-17A by DNCB in E7.Rag-/- skin 
prompted us to test whether myeloid cell subsets as well as lymphocytes contributed to IL-
17A production in this model. Intracellular staining confirmed expression of IL-17A in 
CD45.2+CD11b+ myeloid cells and CD45.2+CD11b- cells isolated from C57BL/6, K14.E7, 
Rag-/- and E7.Rag-/- mice after DNCB treatment (Sup. figure 3.1a). As expected, flow 
cytometric analysis showed a significant increase in the percentage (Sup. figure 3.1b) as 
well as absolute number of IL-17A+CD11b- cells (Figure 3.4a) in K14.E7 skin after DNCB 
treatment, whereas the number of these cells remained unchanged in E7.Rag-/-, C57BL/6 
and Rag-/- mouse skin. Thus, while in K14.E7 skin, lymphocytes induced a significant 
amount of IL-17A after DNCB treatment, in both K14.E7 and E7.Rag-/- mice there was an 
increase in the proportion (Sup. figure 3.1c) and number of IL-17A+CD11b+ cells compared 
to C57BL/6 and Rag-/- mice (Figure 3.4b). Also, DNCB-treated K14.E7 mice had 
approximately 6-fold more IL-17A+CD11b+ cells (12,026 ± 1,234 cells/ear, mean ± SEM) 
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than IL-17A+ CD11b- cells (1,925±354 cells/ear, mean ± SEM), indicating that CD11b+ 
myeloid cells were also a major source of IL-17A in these mice was also (Figure 3.4a and 
3.4b). To further indentify which myeloid cell subsets produce IL-17A in DNCB-treated 
K14.E7 and E7.Rag-/- mice, we analyzed the expression of IL-17A in the macrophage 
(F4/80+), neutrophil (Gr1hi), and dendritic cells (CD11c+MHCII+) fraction of CD11b+ cell 
population. F4/80+ macrophages from both K14.E7 and E7.Rag-/- skin, but not from their 
counterpart controls (C57BL/6 and Rag-/-) showed an increased production of IL-17A after 
DNCB treatment (Figure 3.4c and 3.4d).  Interestingly, neither neutrophils nor dendritic 
cells in K14.E7 mice after DNCB treatment showed staining for IL-17A (Sup. figure 1d). 
Thus, CD11b+F4/80+ macrophages were major contributors of IL-17A induction in DNCB-
treated K14.E7 skin, and this increased production occurred in the absence of T and B 
lymphocytes.  
 
Suppression of IL-17A or arginase-1 attenuates the DNCB-induced 
inflammation in K14.E7 skin 
 
To address whether IL-17A expression is sufficient to trigger the enhanced acute 
inflammation in K14.E7 and E7.Rag-/- skin, we applied DNCB to E7.IL17-/- or IL-17A 
neutralizing antibody-treated K14.E7 and E7.Rag-/- mice. Pretreatment of mice with IL-17A 
neutralizing antibody, when compared to isotype control antibody, caused a significant 
reduction in the ear swelling (Figure 3.5a). Further, histological examination also showed a 
significant reduction in ear thickness and the number of infiltrating leukocytes within the 
dermis of E7.IL17-/- mice or K14.E7 and E7.Rag-/- mice pretreated with anti-IL-17A 
neutralizing antibody, as compared with K14.E7 and E7.Rag-/- mice, respectively one day 
after DNCB treatment (Figure 3.5b).  
 
IL-17A and arginase-1 mediate the enhanced recruitment of neutrophils in 
DNCB -treated K14.E7 skin via CXCL1 and CXCL5 production  
 
Neutralization of IL-17A in K14.E7 mice reduced the DNCB-induced ear swelling on 
day 5 post treatment to a greater extent than suppression of arginase activity (Figure 3.6). 
As IL-17A was shown to promote arginase production, we assessed whether simultaneous 
inhibition of arginase and IL-17A suppressed ear swelling to a greater extent compared to 
blockade of IL-17A alone. If both IL-17A and arginase were inhibited, ear swelling levels 
were similar to mice in which only IL-17A was depleted (Figure 3.6).  
Chapter 3 
 
 78 
We have demonstrated that the hyperinflammatory response in K14.E7 skin is 
manifested by a large recruitment of myeloid cells, particularly neutrophils which account 
for a significant proportion of total infiltrating myeloid cells (Sup. figure 3.2). Deficiency in 
IL-17A or blockade of arginase-1 production significantly reduced the number of 
neutrophils (CD11b+Gr1hi cells) but not of other cell types in K14.E7 skin after one day of 
DNCB application (Figure 3.7a-c). Recruitment of neutrophils is driven by chemokines 
including CXCL1, CXCL2, and CXCL5 (180). These chemokines are highly elevated in 
K14.E7 skin following DNCB treatment. Conversely, the expression level of CXCL1 and 
CXCL5, but not CXCL2, was significantly reduced in E7.IL17-/- skin, and in arginase 
inhibitor-treated K14.E7 skin, suggesting that both IL-17A and arginase were required for 
the induction of these chemokines (Figure 3.7d-f).  
Taken together, our data show that IL-17A contributed to the enhanced production 
of arginase-1 and that IL-17A together with arginase-1, contributed to DNCB-induced 
hyper-inflammatory response in HPV16.E7 expressing skin, possibly by promoting the 
production of CXCL1 and CXCL5 chemokines-mediated recruitment of neutrophils.  
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Figure 3.1- IL-17A from DNCB-treated E7 transgenic skin contributes to the induction 
of arginase in BMDM. (a) C57BL/6, K14.E7, Rag-/- and E7.Rag-/- mice were treated with 
vehicle or DNCB for 4 hours.  Explanted skin was cultured for 24 hours and culture 
supernatant was assessed for induction of BMDM arginase activity (b) Arginase activity in 
BMDM cultured in vehicle or DNCB-treated K14.E7 skin explant supernatants and exposed to 
matched-isotype antibodies or neutralizing antibodies (10 ng/ml) against IL-4, IL-10 or IL-17A. 
(c) Arginase activity in BMDM cultured in supernatants from vehicle or DNCB-treated E7.IL17-
/- or E7.IL17+/- skin explants. Data are means ± SEM, and are representative of two 
independent experiments, each with 4-6 mice per group.* p<0.05, ** p<0.01, NS not 
significant. 
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Figure 3.2- IL-17A enhances recruitment of arginase-1 producing CD11b+Gr1intF4/80+ 
cells to K14.E7 mouse skin following DNCB application. (a) Arginase activity in K14.E7 
and E7.IL17-/- mouse skin after 24 hours of DNCB treatment. (b) and (c) Expression of 
arginase-1 and arginase-2 mRNA transcripts in K14.E7 and E7.IL17-/- mouse skin following 
DNCB application determined by real-time PCR. (d)  Immunohistochemical analysis of F4/80+ 
macrophages in K14.E7 or E7.IL17-/- skin exposed to DNCB. Stained sections are 
representative of 4 mice per group, original magnification x200, scale bar =100 μm. (e) The 
absolute number of infiltrating CD11b+Gr1+F4/80+ cells in K14.E7 and E7.IL17-/- skin one day 
after DNCB treatment was determined by flow cytometry. Data are means ± SEM, and are 
pooled from two independent experiments, each with 4-7 mice per group.* p<0.05, ** 
p<0.001, *** p <0.0001, NS not significant.  
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Figure 3.3- IL-17A is induced by DNCB in both K14.E7 and E7.Rag-/- transgenic skin. (a) 
Quantitative real-time PCR analysis of IL-17A mRNA transcripts in the skin and (b) IL-17A 
production by ELISA in the supernatants of skin explant cultures from C57BL/6, K14.E7, Rag-
/- and E7.Rag-/- mice one day after DNCB (1% (w/v)) treatment or vehicle application. (c) 
Quantitative real-time PCR analysis of IL-17A mRNA transcripts in C57BL/6 treated with a 
10% DNCB (w/v) or in K14.HgH, K14.E7, nor-NOHA treated K14.E7 skin after 1% DNCB 
(w/v) treatment. Data show the mean ± SEM and represent two independent experiments, 
each with 4-5 animals per group.* p<0.05,** p<0.001, NS not significant. 
V
eh
ic
le
 D
N
C
B
V
eh
ic
le
D
N
C
B
V
eh
ic
le
D
N
C
B
V
eh
ic
le
D
N
C
B
0
50
100
150
IL
-1
7
A
 (
p
g
/m
l)
 n
o
rm
a
li
s
e
d
 t
o
 1
0
0
 m
g
 t
is
s
u
e
C57BL/6 K14.E7
**
**
NS
**
3/5 4/5 0/5 0/5 0/5 0/5
Rag-/- E7.Rag
-/-
V
eh
ic
le
D
N
C
B
V
eh
ic
le
D
N
C
B
V
eh
ic
le
D
N
C
B
V
eh
ic
le
D
N
C
B
0.00000
0.00004
0.00008
0.001
0.002
0.003
0.004
R
e
la
ti
v
e
 I
L
-1
7
A
 g
e
n
e
 e
x
p
re
s
s
io
n
C57BL/6 Rag-/-
**
**
NS
K14.E7
NS
E7.Rag-/-
**
2/5 2/5
*
1/5 0/5
a b
c
V
eh
ic
le
10
xD
N
C
B
V
eh
ic
le
D
N
C
B
V
eh
ic
le
D
N
C
B
V
eh
ic
le
D
N
C
B
0.0000
0.0005
0.0010
0.0015
0.0020
0.0025
0.0030
R
e
la
ti
v
e
 I
L
-1
7
A
 g
e
n
e
 e
x
p
re
s
s
io
n
C57BL/6 K14.HgH K14.E7
*
NS
NS
2/5
*
NS
K14.E7
nor-NOHA
Chapter 3 
 
 82 
 
C 5 7 B L /6 K 1 4 .E 7
F 4 /8 0
c
R a g
- / -
E 7 .R a g
- / -
G a te d  o n  l iv e  C D 4 5 .2
+
 C D 1 1 b
+
c e lls
Is o ty p e
V e h ic le
D N C B
IL -1 7A
C
5
7
B
L
/6
K
4
.E
7
R
a
g
- /
-
E
7
.R
a
g
- /
-
0
5 0 0 0
1 0 0 0 0
1 5 0 0 0
N
u
m
b
e
r
 o
f
 I
L
-
1
7
+
 m
a
c
r
o
p
h
a
g
e
s
(
C
D
1
1
b
+
F
4
/8
0
+
)
/e
a
r
C o n tro l
D N C B
*
N S
*
*
N S
*
ba
d
C
5
7
B
L
/6
K
4
.E
7
R
a
g
- /
-
E
7
.R
a
g
- /
-
0
5 0 0
1 0 0 0
1 5 0 0
2 0 0 0
2 5 0 0
N
u
m
b
e
r
 o
f
 I
L
-
1
7
+
C
D
1
1
b
-
 c
e
ll
s
/e
a
r *
*
N S
N S
N S
C
5
7
B
L
/6
K
4
.E
7
R
a
g
- /
-
E
7
.R
a
g
- /
-
0
5 0 0 0
1 0 0 0 0
1 5 0 0 0
N
u
m
b
e
r
 o
f
 I
L
-
1
7
+
C
D
1
1
b
+
 c
e
ll
s
/e
a
r
*
N S
*
*
N S
*
C o n tro l
D N C B
 
 
Figure 3.4- DNCB induced IL-17A is mostly produced by CD11b+F4/80+ macrophages. 
C57BL/6, K14.E7, Rag-/- and E7.Rag-/- mice were treated with vehicle or DNCB, and after 24 
hours cells were isolated from ear skin tissues and stained for IL-17A. (a), (b) and (d) The 
absolute number of IL17A+ CD11b- (a) and IL-17A+ CD11b+ (b) and IL-17A+CD11b+F4/80+ (d) 
cells. (c)-Representative dot plots pre-gated on viable CD45.2+CD11b+ cells and stained with 
F4/80 and IL-17A. Data shows the mean ± SEM and represent two independent experiments 
of 4 animals per experiment.* p<0.05, NS not significant.  
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Figure 3.5- IL-17A promotes ear swelling induced by DNCB in K14.E7 skin.  (a) Ear 
swelling of isotype or anti-IL-17 neutralizing antibody treated K14.E7 and E7.Rag-/- or E7.IL17-
/- mice following DNCB application. Data are means ± SEM, and representative of 2 
independent experiments, each with 4-7 animals per group,* p <0.05, ** p< 0.01, *** p<0.001, 
NS not significant. (b) Histological analysis of isotype antibody or anti-IL-17A neutralizing 
antibody treated K14.E7 and E7.Rag-/- skin or E7.IL17-/- skin.  Hematoxylin and eosin 
sections, original magnification x200, scale bar =100 μm (representative of four mice per 
group).  
Chapter 3 
 
 84 
 
0 1  2 3 4 5
1
1 0
2 0
3 0
4 0
D a y s  a fte r  D N C B  s e n s it iz a t io n

E
a
r
 
s
w
e
l
l
i
n
g
 
(
x
1
0

m
)
V e h ic le  + P B S  tre a te d  E 7 .IL 1 7
- / -
V e h ic le  +  n o r-N O H A  tre a te d  E 7 .IL 1 7
- / -
V e h ic le  + P B S  tre a te d  K 1 4 .E 7
V e h ic le  +  n o r-N O H A  tre a te d  K 1 4 .E 7
D N C B  + P B S  tre a te d  E 7 .IL 1 7
- / -
D N C B  +  n o r-N O H A  tre a te d  E 7 .IL 1 7
- / -
D N C B  + P B S  tre a te d  K 1 4 .E 7
D N C B  +  n o r-N O H A  tre a te d  K 1 4 .E 7
* * * *
* * * *
* * * *
* * * *
# # #
 
Figure 3.6- IL-17A and arginase blockade cause comparable suppression of ear 
swelling in DNCB-treated K14.E7 mouse skin.  Ear swelling of K14.E7 and E7.IL-17-/- mice 
treated with PBS or 500 µg/mouse of nor-NOHA one day before DNCB or vehicle application 
and daily for 5 days. Data are means±SEM, and representative of 2 independent 
experiments, *** p< 0.001(DNCB and PBS-treated K14.E7 skin versus other treatment  
groups), ### p<0.001 (DNCB and nor-NOHA-treated K14.E7 skin versus DNCB-treated 
E7.IL17-/- or DNCB and  IL-17A blocked K14.E7 group). 
 
Chapter 3 
 
 85 
 
 
V
e
h
ic
le
D
N
C
B
V
e
h
ic
le
D
N
C
B
V
e
h
ic
le
D
N
C
B
0 .0 0
0 .0 2
0 .0 4
0 .0 6
0 .0 8
0 .1 0
C X C L 1
R
e
la
ti
v
e
 C
X
C
L
1
 g
e
n
e
 e
x
p
r
e
s
s
io
n
**
**
**
E 7 .IL 1 7
- / -K 1 4 .E 7 n o r-N O H A
V
e
h
ic
le
D
N
C
B
V
e
h
ic
le
D
N
C
B
V
e
h
ic
le
D
N
C
B
0 .0
0 .2
0 .4
0 .6
0 .8
C X C L 2
R
e
la
ti
v
e
 C
X
C
L
2
 g
e
n
e
 e
x
p
r
e
s
s
io
n
N S
**
N S
E 7 .IL 1 7
- / -K 1 4 .E 7 n o r-N O H A
V
e
h
ic
le
D
N
C
B
V
e
h
ic
le
D
N
C
B
V
e
h
ic
le
D
N
C
B
0 .0 0
0 .0 2
0 .0 4
0 .0 6
0 .0 8
0 .1 0
C X C L 5
R
e
la
ti
v
e
  
C
X
C
L
5
 g
e
n
e
 e
x
p
r
e
s
s
io
n
***
**
***
E 7 .IL 1 7
- / -K 1 4 .E 7 n o r-N O H A
d e f
V
e
h
ic
le
D
N
C
B
V
e
h
ic
le
D
N
C
B
V
e
h
ic
le
D
N
C
B
0
2
4
6
8
N e u tro p h ils  (C D 1 1 b
+
G r 1
h i
)
N
u
m
e
b
e
r
 o
f 
c
e
ll
s
/e
a
r
 (
x
1
0
6
) *
*
*
E 7 .IL 1 7
- / -K 1 4 .E 7 n o r-N O H A
a c
V
e
h
ic
le
D
N
C
B
V
e
h
ic
le
D
N
C
B
V
e
h
ic
le
D
N
C
B
0
5 0 0 0 0
1 0 0 0 0 0
1 5 0 0 0 0
2 0 0 0 0 0
D e n d r it ic  c e l ls  (C D 1 1 c
+
M H C II
+ )
N
u
m
e
b
e
r
 o
f 
c
e
ll
s
/e
a
r
N S
N S
N S
E 7 .IL 1 7
- / -K 1 4 .E 7 n o r-N O H A
b
V
e
h
ic
le
D
N
C
B
V
e
h
ic
le
D
N
C
B
V
e
h
ic
le
D
N
C
B
0
5 0 0 0 0 0
1 0 0 0 0 0 0
1 5 0 0 0 0 0
2 0 0 0 0 0 0
T  c e lls  (C D 3
+
)
N
u
m
e
b
e
r
 o
f 
c
e
ll
s
/e
a
r
N S
N S
N S
E 7 .IL 1 7
- / -K 1 4 .E 7 n o r-N O H A
 
 
Figure 3.7- IL-17A and arginase induce chemokine production and neutrophil 
recruitment in  DNCB-treated K14.E7 mouse skin   (a)-(c) The absolute number of 
neutrophils (CD11b+Gr1hi) (a), dendritic cells (CD11c+MHCII+) (b) and T cells (CD3+) (c) in 
K14.E7 mice, E7.IL17-/- mice and arginase inhibitor (nor-NOHA)- treated K14.E7 mice was 
determined by flow cytometry. (d)-(f) Quantitative real-time PCR analysis of CXCL1 (d), 
CXCL2 (e), and CXCL5 (f) transcripts in these mice. Data are means ± SEM, and are pooled 
from two independent experiments (n≥4 mice per group). * p<0.05,** p< 0.01, *** p<0.001, NS 
not significant. 
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Supplementary figure 3.1- Myeloid cells are the major producers of IL-17A in DNCB-
treated K14.E7 skin. (a) Representative dot plots pre-gated on viable CD45.2+ cells and 
stained with CD11b and IL-17A. (b)-(c) The frequency of IL-17A+ CD11b-, IL-17A+ CD11b+ in 
C57BL/6, K14.E7, Rag-/- and E7.Rag-/- mice one day after DNCB treatment. Data are means 
± SEM, and are pooled from two independent experiments (n= 4 mice per group).* p<0.05, 
NS not significant. (d) Representative dot plot of IL-17A/CD11c or IL-17A/Gr1 populations. 
Cells were pre-gated on viable CD45.2+ MHCII+ cells for dendritic cell analysis and CD45.2+ 
cells for neutrophil analysis.  
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Supplementary figure 3.2- K14.E7 mouse skin exhibits enhanced recruitment of 
neutrophils and macrophages after DNCB treatment.  
(a) Representative dot plot from vehicle/DNCB treated C57BL/6 and K14.E7 skin showing 
gating strategy for flow cytometric analysis of dendritic cells (CD11c+MHCII+), macrophages 
(CD11b+F4/80+) and neutrophils (CD11b+Gr1hi). Plots are representative of 4 mice per group.  
(b) The frequencies of these cell subsets in C57BL/6 and K14.E7 (n=4) skins after one day of 
DNCB treatment.  Data are ploted as the mean % of viable CD45.2+ cells ± SEM. * p<0.05, 
NS not significant.  
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Supplementary figure 3.3- BMDM showed enhanced arginase production in response 
to LPS and IL-4 or IL-10 stimulation. (a)-(b) BMDM cells obtained from C57BL/6 mice were 
pretreated with 10 ng/ml of monoclonal antibody against IL-4 (a) or IL-10 (b) or matched-
isotype control antibody before stimulation with LPS (100 ng/ml) and recombinant IL-4 or IL-
10 (10 ng/ml) for 24 hours. Total protein was isolated and arginase activity was determined. 
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Supplementary figure 3.4- IL-4 and IL-10 are mainly produced by lymphocytes in DNCB 
-treated K14.E7 skin. (a)-(b) Quantitative real-time PCR analysis of IL-4 (a) and IL-10 (b) in 
K14.E7  or E7.Rag-/- skin one day after DNCB or vehicle treatment. Data are means ± SEM 
and representative of two independent experiments, each with n≥4 mice per group. p<0.05,** 
p< 0.01, NS not significant. 
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Discussion 
 
Here, we show that induction of IL-17A contributes to a significantly enhanced 
chemokine-mediated recruitment of neutrophils and arginase-1 producing macrophages in 
skin expressing the E7 protein of HPV16 treated with DNCB, when compared with non-
transgenic skin similarly treated with DNCB. We have previously demonstrated that 
HPV16.E7 expressing skin exposed to DNCB develops a hyperinflammatory response which 
is associated with recruitment of myeloid cells producing arginase-1 and that arginase-1 
activity contributes to the enhanced inflammation (170). Here, ex-vivo  skin explant culture 
supernatants induced enhanced arginase activity in BMDM in immune competent and Rag-/- 
mice, confirming that arginase-1 induction in K14.E7 skin exposed to DNCB was dependent 
on innate immune cells rather than T and B lymphocytes (170). 
 IL-4 and IL-10 which have been well described as potent inducers of arginase-1 in 
macrophages (171) and as well as important regulators of cutaneous inflammation (74) were 
found to be induced in K14.E7 skin, but not in wild-type C57BL/6 skin, suggesting possible 
involvement of these cytokines in arginase-1 regulation. Consistent with previous reports 
(172, 181), we found that BMDM treated with IL-4 and LPS significantly induced arginase 
activity and that arginase-1 induction was completely abrogated in the presence of anti-IL-4 or 
anti-IL-10 neutralizing antibody (Sup. figure 3.3).  However, IL-4 and IL-10 blockade failed to 
reduce arginase-1 activity in BMDM treated with skin explant supernatant from DNCB -treated 
K14.E7 skin. Furthermore, the induction of Th2 cytokine IL-4 and IL-10 was abrogated in 
DNCB-treated E7.Rag-/- skin (Sup. figure 3.4), arguing against a role for these cytokines in 
arginase-1 induction in K14.E7 skin since the enhanced production of arginase-1 also 
occurred in the absence of lymphocytes.  
Our observation that blockade of IL-17A caused a significant reduction in arginase-1 
are consistent with a recent study which suggested that IL-17A indirectly mediates arginase-1 
production in macrophages through inducing cyclooxygenase-2 (COX-2) production by 
human cervical cancer cell line HeLa (175). Moreover, IL-17A has been shown to mediate 
arginase-1 induction by promoting infiltration of inflammatory monocytes to the site of 
inflammation (182). In support of this, blockade of IL-17A in DNCB-treated K14.E7 skin 
significantly decreased the number of arginase producing CD11b+Gr1intF4/80+ cells. IL-17A 
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might act as an up-stream enhancer of local arginase activity by enhancing recruitment of 
inflammatory macrophages.  
IL-17A and arginase-1 were not induced in the hyperinflammation established in 
nontransgenic skin exposed to 10% DNCB, suggesting the involvement of HPV16.E7 
oncoprotein or HPV16.E7-induced hyperproliferative epithelium in the induction of these 
molecules. A recent study in our laboratory suggested that expression of HPV16.E7 
oncoprotein leads to elevated production of IL-17A in the skin of K14.E7 mice and 
hyperplastic cervical tissue (35). To date, there is no evidence in the literature that HPV16.E7 
protein can directly affect the transcription of arginase. Furthermore, the E7-associated 
mechanisms that are responsible for IL-17A or arginase-1 induction in association with DNCB 
treatment remained unknown. It is speculated that E7 oncoprotein expression interacts with 
DNCB as an inflammasome activator, which subsequently drives the secretion of active IL-
1β and IL-6 (91). These inflammasome-drived cytokines have been shown to promote IL-17A 
production by not only Th17 but also “non-T cells”, innate lymphoid cells (183). In support to 
this hypothesis, we previously demonstrated the induction of both IL-1β and IL-6 in K14.E7 
skin and not in nontransgenic skin following DNCB treatment.  
IL-17A production was produced by CD11b+F4/80+ macrophages in DNCB-treated 
E7.Rag-/- skin in which Th17 and γδT cells are absent, confirming the findings of others that 
lymphocyte subsets are not exclusive sources of IL-17A (177, 183). The proportion of IL-17A 
producing macrophages was significantly reduced in E7.Rag-/- skin compared to K14.E7 skin, 
suggesting that lymphocytes contributed significantly to the induction of IL-17A in these cells. 
However, this subset appeared to be a major producer of IL-17A in K14.E7 skin, as IL-17A+ 
macrophages markedly outnumber IL-17A+ T cells in K14.E7 skin. Thus, it is possible that IL-
17A secreting macrophages might stimulate themselves in an autocrine manner leading to 
enhanced production of arginase-1. Alternatively, IL-17A and arginase-1 are produced by two 
different subsets of CD11b+Gr1intF4/80+ cells. Indeed, further characterizing the IL-17A-
producing subset showed that they do not express MHC-II, while arginase-1 producing cells 
express MHC-II (data not shown). Further, it is noted that suppression of IL-17A in K14.E7 
mice could not completely abrogate arginase-1 induction, suggesting that IL-17A is not the 
only factor promoting arginase-1 induction.  
IL-17A neutralization in K14.E7 skin as well as E7.Rag-/- resulted in reduced DNCB-
induced ear swelling response, suggesting that macrophage-derived IL-17A contributed to the 
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hyperinflammation induced by DNCB in K14.E7 skin. Although Th17 and other lymphocyte 
subsets are regarded as primary sources of IL-17A and have been implicated as effector cells 
of cutaneous inflammation, our findings are in agreement with a recent study that shows that 
alveolar macrophages as a source of IL-17A which mediated allergic lung inflammation in a 
murine model of asthma (177). 
The mechanisms driving the initiation of inflammation in this model remained 
unidentified so far, as the induction of ear swelling, measured at one day post DNCB 
application, did not change regardless of whether IL-17A or arginase was suppressed. 
However, our data clearly shows that IL-17A and arginase are significantly required for the 
ongoing hyper-inflammation in K14.E7 after the second day. Simultaneous blockade of both 
IL-17A and arginase activity did not further suppress the ear swelling response in DNCB-
treated K14.E7, compared to blocking either alone. In addition, suppression of arginase 
activity did not reduce IL-17A production in DNCB-treated K14.E7 skin, further confirming that 
arginase-1 and IL-17A act in the same pathway and IL-17A is likely to be an up-stream 
mediator of arginase-1.  
DNCB-induced hyperinflammation in K14.E7 skin is manifested by the infiltration of 
myeloid cells, particularly neutrophils. Blockade of either IL-17A or arginase resulted in a 
decrease in the number of infiltrating neutrophils, thereby reducing neutrophilic inflammation 
caused by DNCB in K14.E7 skin. CXCL1, CXCL2 (MIP2) and CXCL5, that signal through 
CXCR2 receptors, are the most potent neutrophil chemoattractants and appear to selectively 
promote neutrophil infiltration (178). These chemokines were all induced in K14.E7 skin after 
DNCB treatment, IL-17A deficiency and suppression of arginase-1 in K14.E7 skin significantly 
reduced the expression of CXCL1 and CXCL5, suggesting that CXCL1 and CXCL5 are 
important mediators for IL-17A and arginase to promote the hyperinflammation in K14.E7 
skin. Our findings are supported by previous studies that IL-17A promotes neutrophil 
infiltration via CXCL1 (184) or CXCL5 (185) induction during acute inflammatory responses. 
Further, arginase specific inhibitor treatment significantly ameliorated pulmonary inflammation 
and airway fibrosis in guinea pig repeatedly exposed to LPS. The alleviated inflammation in 
these animals was concomitant with decreased neutrophil infiltration (122). However, whether 
IL-17A has a direct role in neutrophil recruitment and chemokine induction or acts through 
arginase-1 remains unknown.  
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In summary, the present study shows that DNCB application to HPV16.E7 expressing 
skin generates the acute hyperinflammation through a previously undescribed pathway at 
least involving IL-17A which enhances arginase-1 production. This study also identifies the 
E7-associated proinflammatory roles for IL-17A and arginase-1 that might be considered as 
potential targets to stimulate innate immunity which is speculated to support antigen specific 
immune-therapies for the treatment of HPV-associated diseases.  
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3.3 Additional data not described in the article 2 
 
3.3.1 CCL2/MCP1 and CCL7/MCP3 are involved in IL-17A mediated-recruitment of 
macrophages  
 
Data shown in article 2 demonstrated that IL-17A promoted monocyte/macrophage 
recruitment to DNCB-treated K14.E7 skin. Monocyte trafficking during inflammation can be 
guided by C-C motif chemokine ligands including CCL2, CCL7, CCL8 and CCL12 (186). 
DNCB application to K14.E7 skin caused a significant induction of CCL2 and CCL7 mRNA 
(Figure 3.8a and 3.8b). The mRNA expression levels of these chemokine were significantly 
reduced in IL-17A deficient K14.E7 skin, suggesting the contribution of IL-17A to the induction 
of CCL2 and CCL7. Conversely, there was no change in the mRNA expression levels of other 
chemokines including CCL8 and CCL12 in K14.E7 skin after DNCB treatment (Figure 3.8c 
and 3.8d). There are no chemokines or receptors which have been identified so far have a 
specific role in monocyte or macrophage infiltration (187). Nevertheless, CCL2 and its closely 
related analogue, CCL7, which can be produced by a variety of cell types including 
macrophages, neutrophils, fibroblasts and epithelial cells, have been identified as major 
mediators of the CCR2+ monocyte infiltration during acute inflammation (188-190). 
Consistently, our finding suggests that IL-17A might promote macrophage/monocyte 
infiltration in DNCB-treated K14.E7 skin through the upregulation of CCL2 and CCL7.  
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Figure 3.8- IL-17A promotes CCL2/MCP1 and CCL7/MCP3 production in K14.E7 skin 
after DNCB application. (a)-(d) CCL2, CCL7, CCL8 and CCL12 mRNA expression in 
K14.E7 and E7.IL-/- skin one day post vehicle or DNCB application. Data indicate SEM± 
mean, n≥ 5 mice per group.*, p<0.05; **, p<0.001; ***, p<0.0001; NS, not significant.  
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3.3.2 HPV16.E7 protein is required for IL-17A and aginase mediated-
hyperinflammation 
 
To establish the role of E7 protein in the induction of arginase-1, we examined the 
induction of this molecule in C57BL/6 mice treated with a 10-fold higher dose of DNCB. These 
animals developed ear swelling level comparable to that observed in K14.E7 mouse skin 
exposed to a lower level of DNCB (Figure 3.9b). However, they were unable to induce 
arginase-1 (Figure 3.9a) as well as IL-17A (Figure 3.3c) mRNA expression. Furthermore, 
blockade of IL-17A or arginase activity was unlikely to reduce the level of ear swelling of 
these animals (Figure 3.9b). These findings confirm that HPV16.E7 protein is required for the 
induction of IL-17A and arginase-1 and establishment of hyperinflammation mediated by 
these factors. However, the mechanism of action of E7 protein in the regulation of IL-17A and 
arginase-1 in response to DNCB application will require further studies.  
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Figure 3.9- IL-17A and arginase-1 are not involved in DNCB-induced hyperinflammation 
in wild-type C57BL/6 transgenic skin. (a) Real-time PCR analysis of IL-17A gene 
expression in C57BL/6 and K14.E7 skin at day 1 post 10% or 1% of DNCB application, 
respectively. (b) Ear swealing of C57BL/6 mice pre-treated with PBS or arginase inhibitor and 
IL-17-/- mice before application with vehicle or 10% of DNCB. Data are means ± SEM, n= 4-6 
mice per group.* p<0.05, NS not significant. 
 
 
Vehicle 10% DNCB Vehicle 1% DNCB
0.00000
0.00002
0.00004
0.00006
0.00008
0.00010
0.0001
0.0002
0.0003
0.0004
0.0005
0.0006
IL-17A
R
e
la
ti
v
e
 g
e
n
e
 e
x
p
re
s
s
io
n
C57BL/6  K14.E7
*
1 2 3 4 5
0.5
1.0
1.5
2.0
10
20
30
40
10% DNCB treated C57BL/6
Vehicle treated C57BL/6
Vehicle treated IL-17-/-
10% DNCB treated IL17
-/-
Days after DNCB sensitization

E
a
r 
s
w
e
ll
in
g
 (
x
1
0

m
)
Vehicle+nor-NOHA treated C57BL/6
10% DNCB+nor-NOHA treated C57BL/6
NS
NS
NS
NS
NS
a
b
Chapter 3 
 
 98 
3.3.3 DNCB application results in induction of IL-1β and IL-6 in both K14.E7 and 
E7.Rag-/- skin 
 
It has been shown that innate immune response to DNCB is initiated by the activation 
of inflammasome signaling pathways that drive the secretion of active IL-1β and IL-6 (91, 
147). These inflammasome-drived cytokines were reported to promote IL-17A production by 
lymphocyte and “non-T cells”, innate lymphoid cells (183). Furthermore, IL-6 when combined 
with TGFβ was described as the strongest inducer of Th17 cell differentiation while IL-23 is 
thought to act on the expansion, maintenance of Th17 cells (83). However, little is known 
about the regulation of IL-17A in “non T cells”. As shown in the article 2 that the myeloid cells-
derived IL-17A promoted lymphocyte independent inflammatory response to DNCB in K14.E7 
skin, we sought to investigate the production of possible inducers of IL-17A in K14.E7 and 
E7.Rag-/- skin. IL-6 and IL-1β mRNA expression were significantly induced in K14.E7 and 
E7.Rag-/- skin and not in their wild-type counterpart controls (C57BL/6 and Rag-/-) (Figure 
3.10a and 3.10b). In contrast, the level of IL-23 mRNA was significantly reduced in both 
K14.E7 and E7.Rag-/- skin (Figure 3.10c). It is noted that E7.Rag-/- skin expressed a greater 
base level of IL-23 mRNA than K14.E7 skin. There was no change in the level of TGFβ 
mRNA expression in both K14.E7 and E7.Rag-/- skin following DNCB treatment (Figure 
3.10d). These results suggest that the DNCB- associated induction of IL-1β and IL-6 is driven 
by innate immune cells in K14.E7 skin, indicating their possible involvements in the regulation 
of IL-17A or arginase-1 in myeloid cells.   
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Figure 3.10- IL-1β or IL-6 and not IL-23 or TGF-β are induced by innate immune cells in 
K14.E7 skin. (a)-(d) Relative gene expression of IL-1β (a), IL-6(b),  IL-23(c) and TGF-β (d) in 
C57BL/6, K14.E7, Rag-/- and E7.Rag-/- skin at one day following DNCB application. Data are 
means ± SEM, n= 4-9 mice per group.* p<0.05, *** p<0.0001, NS not significant. 
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3.3.4 DNCB-induced acute inflammation combined with HPV16.E7 peptide 
vaccination is unable to reject K14.E7 skin graft 
 
Previous investigations have reported that K14.E7 skin is not spontaneously rejected 
when transplanted onto a syngeneic immunocompetent recipient animal which is capable of 
rejecting other non-self antigen expressing skins. Furthermore, vaccination with HPV16.E7 
peptide or protein was unable to reject K14.E7 skin graft despite the induction of specific 
immune responses, including E7-specific CD8+ T cells. Thus, these findings confirm that the 
expression of HPV16.E7 in the epithelium induces a local suppressive environment and the 
subversion of antigen-specific CD8+ T cells (44, 54). Since topical application of DNCB was 
clinically used for the treatment of HPV-associated lesions, we speculated that stimulation of 
innate immunity by DNCB along with antigen-specific immunization might disrupt the local 
suppressive environment and restore the effector function of adaptive immunity. To address 
this hypothesis, we grafted wild-type C57BL/6 or K14.E7 skin onto C57BL/6 recipients, and 
subsequently performed vaccination with HPV16.E7 peptide and topical application with 
vehicle or DNCB (Figure 3.11a). As expected, graft rejection did not occur when vaccinated 
K14.E7 and C57BL/6 grafts were treated with vehicle. DNCB treatment along with vaccination 
caused moderate inflammation in C57BL/6 skin graft. Conversely, these treatments caused 
necrosis and dramatic shrinkage of K14.E7 skin graft on day 14 post-grafting (Figure 3.11b). 
Nevertheless, as the inflammation is resolved, at 20 days post grafting, the original border 
and shape of K14.E7 graft was retrieved despite of the loss of proximal half of the original 
graft. The graft is considered to be rejected if it showed the signs of ulceration or necrosis to 
>80% of the graft (44). Based on these criteria, DNCB-induced hyperinflammation combined 
with specific immunization was unable to completely reject K14.E7 skin graft even after a 
second treatment of DNCB and E7 vaccination (data not shown). Histologically, at 20 days 
post-grafting, DNCB-treated K14.E7 graft showed hyperplastic epidermis and increased 
infiltration of immune cells, as seen in normal K14.E7 skin (Figure 3.12), confirming that the 
combination therapy involving DNCB application and E7 immunization is unlikely to induce 
the complete rejection of K14.E7 skin graft.  
  
 
 
Chapter 3 
 
 101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11- DNCB treatment combined with HPV16.E7 peptide vaccination fails to 
induce complete rejection of K14.E7 graft. (a) Schematic representation of peptide 
immunization with or without 50 μg of HPV16.E7 peptide per mouse and vehicle or DNCB 
(1% w/v) application of C57BL/6 and K14.E7 grafts (n=8 mice per group).  (b) Representative 
photographs taken before (day 11 post-grafting), 3 days (day 14 post-grafting) and 9 days 
(day 20 post grafting) after vehicle or DNCB application.  
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Figure 3.12- Histological sections showing epidermal hyperplasia and cellular infiltrate 
in E7-vaccinated and DNCB-treated K14.E7 graft. Hematoxylin and eosin stain of C57BL/6 
and K14.E7 graft on day 25 post-grafting, original magnification × 200, scale bar=100 μm 
(Representative of at least 8 grafts per group). 
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Vehicle
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3.4 Supplementary method 
 
Skin grafting 
 
Donor ear skin was transplanted onto recipient flanks as previously described (42, 53). 
Briefly, dorsal and ventral ear halves excised from donor mice were placed on the thoracic 
flanks of anesthetized recipient mice. Grafts were held in place with antibiotic-permeated 
gauze (Bactigras; Smith and Nephew, London, UK) and bandaged with micropore tape and 
Flex-wrap (Lyppard, Queensland, Australia). Bandages were removed 7 days after grafting, 
and grafts were monitored daily for loss of distinct border and visible signs of ulceration or 
necrosis to >80% of the graft, which was defined as graft rejection. 
 
Immunization and DNCB treatment scheme 
 
After removing bandages, grafted mice were immunized subcutaneously at the flank 
with 100 μg/mouse of GF001 peptide (H-2Db–restricted minimal CTL epitope of HPV16 E7 
protein, aa sequence = RAHYNIVTF) emulsified in Complere Freund’s adjuvant as indicated 
(Sigma, MO, USA). Immunization was repeated with incomplete Fruend’s adjuvant on day 11 
post-grafting and 50 μl of 1% (v/v) DNCB was topically applied onto skin graft region. Photos 
of grafts were taken daily to monitor graft rejection. 
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3.5 Conclusion 
Chapter 2 demonstrated the significant contribution of arginase-1 to the DNCB-induced 
inflammation in K14.E7 skin. In this third chapter, my results showed that HPV16.E7 
expressing skin developed a hyperinflammatory response to DNCB through a pathway at 
least involving IL-17A which promotes arginase-1 production. Furthermore, this study 
identified the E7 associated- proinflammatory role of macrophage-derived IL-17A and 
arginase-1 in the stimulation of neutrophil infiltration via CXCL1 and CXCL5.  
Additionally, I observed the lymphocyte- independent induction of IL-1β and IL-6 which 
might be associated with activation of inflammasome signaling in K14.E7 skin in response to 
DNCB, thereby leading to the induction of IL-17A and arginase-1. 
Lastly, I have shown that the combination therapy involving HPV oncoprotein specific 
immunization and DNCB mediated-innate immune activation was insufficient to break the 
tolerance of HPV16.E7 oncoprotein.  
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4.1. Topical application of DNCB to HPV16.E7 expressing skin causes lymphocyte-
independent hyperinflammation  
 
 Previous studies using the K14.E7 skin transplantation model of HPV-associated human 
squamous cancer, have shown that a 14.E7 skin graft is not spontaneously rejected by an 
immunocompetent recipient animal despite the induction of specific immune response by 
immunization with E7 protein. This finding indicates that the HPV16.E7 oncoprotein induces 
a locally immunosuppressive environment which subverts the host innate immunity, thereby 
leading to viral persistent infection and carcinogenesis. Effective immune-therapies targeting 
HPV-associate cancer are thus required to overcome the local suppressive environment.  
 Topical application of DNCB, an immune-enhancer, resulted in a greater than 80% 
regression of HPV-associated lesions including alopecia areata, viral warts, and basal and 
squamous cell carcinomas (191). In line with these clinical findings, a previous study using a 
mouse model of melanoma showed that combination therapy involving the simultaneous 
application of DNCB with systemic administration of decarbazine, a DNA alkylating agent, 
caused an enhanced cytolytic effector function of CD8+ T cells and tumor regression (192).  
 Although clinical use of DNCB has been limited due to its mutagenic and carcinogenic 
effects, understanding the underlying mechanisms of how DNCB treatment alters the local 
immune environment induced by HPV16.E7 oncoprotein might lead to better treatment 
options for HPV persistently infected patients. The present study shows that a single 
exposure to DNCB causes an acute hyperinflammatory response in K14.E7 skin which is not 
seen in non-transgenic mice. This finding is consistent with the clinical observation that 
DNCB application evokes more vigorous inflammation in tumor tissues than in surrounding 
normal skin (193).  
 It has been well established that the clinical effect of DNCB is attributable to its ability to 
boost the T cell-mediated immune responses (69). Interestingly, data shown in chapter 2 
demonstrated that the hyperinflammation after a single exposure to DNCB also occurred in 
E7.Rag-/- skin and is therefore independent of antigen specific cell-mediated immunity.  
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4.2 HPV16.E7-induced cutaneous hyperinflammation to DNCB is associated with 
enhanced myeloid cell infiltration and IL-4, IL-10 and IL-17A production 
 
There is limited data concerning the topical DNCB effect on the innate immunity. 
DNCB has been described as a “danger signal” which can trigger the NALP-3 inflammasome 
in keratinocytes or DC (91, 147, 194), resulting in production of proinflammatory cytokines 
including IL-6, IL-1β during early inflammatory response (148, 149). We indeed detected T 
and B lymphocyte-independent induction of IL-6 and IL-1β mRNA in DNCB-treated K14E7 
skin, indicating the possible contribution of these cytokines in regulating the 
hyperinflammation.  
Furthermore, it has been shown that these molecules exert their immune-stimulatory 
effects through recruitment of leukocytes and further induction of a wide range of cytokines 
including Th1, Th2 cytokines, IL-17A and IL-22 in these cells (195-197). In support of this 
notion, the hyperinflammation in K14.E7 skin was manifested by an increased number of 
inflammatory myeloid cells in the dermis and the induction of IL-4, IL-10, IL-17A, but not Th1 
cytokines including IFNγ and TNFα. Although Th2 cytokines and IL-17A have been previously 
reported to correlate with HPV-associate tumor progression, the mechanisms of action of 
these molecules have not been elucidated yet (198, 199). In contrast, a recent study has 
demonstrated that Listeria-based immune therapy induces IL-17A production which fosters 
the regression of tumor in HPV transplantable mouse model (32). In addition, IL-17A-derived-
γδ T cells is critically required for optimal anti-tumor function of CD8+ T cells and 
chemotherapeutic efficacy (200).  
 
4.3 DNCB-induced IL-17A, but not IL-4 and IL-10 mediates arginase-1 induction by 
macrophages in K14.E7 skin 
 
Findings in chapter 2 showed that arginase-1 and arginase activity were significantly 
induced in CD11b+F4/80+Gr1intLy6C+Ly6G- monocyte/macrophages infiltrating to DNCB-
treated K14.E7 skin but not in nontransgenic control animals. Cytokines including IL-4, IL-10 
and IL-17A have been reported as important inducers of arginase-1 by myeloid cells, an 
important regulator of innate immunity (150, 175). The induction of Th2 cytokines including IL-
14 and IL-10 was entirely diminished in DNCB-treated E7.Rag-/- skin in which arginase 
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induction occurred, arguing against a role for these cytokines in the regulation of arginase-1 in 
K14.E7 skin. Furthermore, we showed in chapter 3 that blockade of IL-4 or IL-10 was unlikely 
to abrogate the induction of arginase-1 in BMDM stimulated with supernatant from DNCB-
treated K14.E7 skin explants. In contrast, IL-17A mRNA expression was shown to be induced 
in E7.Rag-/- skin and contributed to the induction of arginase-1 in BMDM as well as K14.E7 
skin following DNCB application. In line with this finding, IL-17A has been recently shown to 
promote arginase-1 expression in macrophages through activation of the COX-2/PGE2 
pathway in HPV-positive cancer cells. Indeed, we also detected the induction of PGE2 
synthase (Table 2.1) in K14.E7 skin but not in nontransgenic skin after DNCB application, 
suggesting that additional studies are required to dissect the link of IL-17A and this molecule. 
Furthermore, Nishikawa et al. (2014) reported that IL-17A was involved in the 
enhanced recruitment of CD11b+Ly6C+MHCII+ macrophages which produce arginase-1 
during intestinal inflammatory response in a mouse model of colitis (201). Consistent with this 
observation, data shown in chapter 3 demonstrated a significant reduction in the number of 
CD11b+Gr1int cells in E7.IL17-/- skin after DNCB application, suggesting one action of IL-17A 
on the induction of arginase in K14.E7 skin is to increase recruitment of arginase-1 producing 
myeloid cells. Inflammatory monocytes which express the CCR2 receptor are recruited from 
the peripheral blood circulation to the site of inflammation in K14.E7 skin in response to CCR2 
ligands including CCL2 (MCP1), CCL7 (MCP3), CCL8 (MCP2) and CCL12 (MCP5) (186). 
The present study showed that CCL2 and CCL7 (but not CCL8 and CCL12) were upregulated 
in K14.E7 after DNCB application and that IL-17A significantly contributes to the induction of 
these chemokines. These findings were supported by a previous study of airway inflammation 
showing that IL-17A stimulated monocyte chemotaxis occurs through induction of CCL2 and 
CCL5 in lung epithelial cells (202).  
It is noted that suppression of IL-17A in K14.E7 mice could not completely abrogate 
arginase-1 induction, suggesting that IL-17A is not the only factor promoting arginase-1 
induction. IL-6 or COX-2/PGE2 has each been shown to induce IL-17A and arginase 
production in macrophage (103, 203-205). Therefore, further studies are required to examine 
the link of these molecules with IL-17A or arginase induction in K14.E7 skin.  
 
4.4 Macrophage derived-IL-17A and arginase mediate DNCB-induced 
hyperinflammation in K14.E7 skin 
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HPV16.E7-associated CD11b+F4/80+ macrophages induced a greater level of IL-17A 
in response to DNCB than lymphocytes, suggesting that this cell population is the dominant 
source of IL-17A in this response. Furthermore, deficiency in IL-17A production caused a 
significant reduction in the level of DNCB-induced inflammation in both K14.E7 and Rag.E7-/- 
skin, demonstrating that macrophage-derived IL-17A is important for DNCB-induced 
hyperinflammation in the absence of T and B cells. Although Th17 and other lymphocyte 
subsets are regarded as primary sources of IL-17A and have been implicated as effector cells 
of cutaneous inflammation, our findings are in agreement with a recent study showing that 
alveolar macrophages as a source of IL-17A mediated allergic lung inflammation in a murine 
model of asthma (177).  
Arginase can function either as a proinflammatory or immunosuppressive mediator 
depending on the inflammatory context. Lepique et al (2009) showed that in a HPV-16 
induced transplantable tumor model, macrophages expressing high levels of arginase-1 
facilitate tumor growth by dampening antitumor T cell function (116). Data shown in chapter 2 
demonstrated the proinflammatory function of arginase-1 in K14.E7 skin exposed to DNCB 
was blocked in the presence of a specific arginase inhibitor, alleviating DNCB-induced 
inflammation. In line with these findings, arginase-1 produced by macrophages has been 
shown to be responsible for the pathophysiology of asthma which is a complex disease 
manifested by allergic airway inflammation and airway hyperreactivity. In mouse models of 
asthma, arginase-1 drives allergic inflammatory response in lung epithelial cells through the 
modulation of NFκB signaling pathway (120, 121). Furthermore, treatment with an arginase 
specific inhibitor, ABH, significantly ameliorated pulmonary inflammation and airway fibrosis in 
guinea pigs repeatedly exposed to LPS. The alleviated inflammation in these animals was 
concomitant with decreased IL-8 production and neutrophil infiltration (122).  In accordance 
with this study, we found that blockade of either IL-17A or arginase activity resulted in a 
decrease in the number of infiltrating neutrophils, thereby reducing neutrophilic inflammation 
caused by DNCB in the K14.E7 skin. CXCL1, CXCL2 and CXCL5, which signal through 
CXCR2 receptors, are the most potent neutrophil chemoattractants and appear to selectively 
promote neutrophil infiltration (178). These chemokines were all induced in K14.E7 skin after 
DNCB treatment, However, IL-17A deficiency and suppression of arginase-1 in K14.E7 skin 
significantly reduced the expression of CXCL1 and CXCL5, suggesting that CXCL1 and 
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CXCL5 are important mediators for IL-17A and arginase to promote the hyperinflammation in 
K14.E7 skin. Our findings are supported by previous studies that IL-17A promotes neutrophil 
infiltration via CXCL1 (184) or CXCL5 (185) induction during acute inflammatory responses. 
However, whether IL-17A has a direct role in neutrophil recruitment and chemokine induction 
or acts through arginase-1 remains unknown.  
Suppression of NO production by iNOS is one possible mechanism by which arginase-
1 mediates hyperinflammation. Endothelium-derived NO was reported to suppress the 
expression of adhesion molecules such as vascular cell adhesion molecule-1 and intercellular 
adhesion molecule-1 (123), thereby inhibiting vascular inflammation. Paradoxically, NO 
produced by neutrophils has been shown to enhance vascular permeability, erythema and 
infiltration of innate immune cells to the site of inflammation (206). As shown in chapter 2, 
iNOS was induced in K14.E7 skin following DNCB treatment despite the induction of arginase 
activity. Furthermore, DNCB-induced arginase activity in K14.E7 skin favored, rather than 
suppressed, NO production. Thus, we speculated that arginase enhanced NO production in 
DNCB treated K14.E7 skin, possibly through promoting recruitment of neutrophils which were 
previously described as major producers of NO during cutaneous inflammation (166).  
Simultaneous blockade of IL-17A and arginase was unable to further suppress DNCB-
induced ear swelling compared to suppression either arginase or IL-17A alone. Furthermore, 
suppression of arginase did not have an impact on IL-17A expression in DNCB-treated 
K14.E7 skin. Together, these findings suggested that arginase -1 is a downtream effector 
molecule of IL-17A and that IL-17A and arginase mediated DNCB-induced hyperinflammation 
in K14.E7 skin.  
 
4.5 The involvement of HPV16.E7 protein in IL-17A and arginase induction 
 
The present study showed that a single exposure to DNCB causes an acute 
hyperinflammatory response in K14.E7 skin which is not seen in non-transgenic mice or in 
other transgenic skins including K14.hGh and K5.OVA, suggesting the involvement of  the 
HPV16.E7 oncoprotein in the generation of the hyperinflammation. Additionally, data shown in 
chapter 3 reported that IL-17A and arginase-1 were not induced in the hyperinflammation 
established in nontransgenic skin by exposure to 10% DNCB, further demonstrating the 
crosstalk between HPV16.E7 oncoprotein expressed in the epithelium and the induction of 
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these innate immune molecules. There is no evidence in the literature that HPV.E7 protein 
can directly affect the transcription of arginase, and we have shown RNA data to that effect 
from the mouse model. Likewise, RNAseq data (data in preparation for publication) showed 
the impact of E7 expression on a wide range of genes but not on Arginase-1 or 2. A recent 
study in our laboratory suggested that expression of the HPV16.E7 oncoprotein leads to the 
elevated production of IL-17A in the skin of K14.E7 mice and hyperplastic cervical tissue (35). 
However, the E7-associated mechanism of IL-17A and arginase-1 induction in response to 
DNCB application remains unknown. It is speculated that E7 expression interacts with DNCB 
as an inflammasome activator to alter arginase induction in myeloid cells. Indeed, it has been 
reported that the acute cutaneous inflammatory response to DNCB is initiated by the 
activation of inflammasome signaling pathways, which drive the secretion of active IL-1β and 
IL-6 (91). These inflammasome-driven cytokines were reported to promote IL-17A production 
by not only Th17 but also “non-T cells”, innate lymphoid cells (183). In support of this 
hypothesis, in chapter 3, we demonstrated the induction IL-1β and IL-6 in both K14.E7 and 
E7.Rag-/- skin following DNCB treatment. Of note, the precise mechanisms driving the 
initiation of inflammation in this model remain unidentified so far, as the induction of ear 
swelling, measured at one day post DNCB application, did not change regardless of whether 
IL-17A or arginase was suppressed. Further, studies are thus required to dissect the 
implication of these cytokines in the induction of IL-17A and arginase-1 in macrophages.  
 
4.6 Conclusion and Clinical implication 
 
Current therapeutic strategies targeting HPV-associated diseases have largely failed at 
clinical stages, despite promising results in animal models. One possible explanation for 
failure is that although these approaches induce HPV oncoprotein specific CD4+ and CD8+ T 
cell responses, they do not target the virus-driven immunosuppressive environment that 
inhibits the effector functions of T cells. The present study using the HPV16.E7 transgenic 
mouse model shows that DNCB application generates the lymphocyte-independent acute 
cutaneous hyperinflammation that might support antigen specific immune therapies. 
Furthermore, results presented in this thesis demonstrated a previously undescribed 
molecular and cellular pathway for the development of DNCB-induced hyperinflammation in 
which IL-17A and arginase play pro-inflammatory roles (Figure 4.1).  
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Thus, induction of IL-17A or arginase-1 by administrating recombinant IL-17A and 
arginase-1 protein might be considered as a supplementary strategy to establish acute 
hyperinflammation in HPV-infected patients.  Although, there are numerous reports regarding 
IL-17A and arginase-1 showing their contributions to immunosuppression, our findings are 
consistent with recent studies suggesting that these molecules are involved in the activation 
of innate immune response in asthma. Furthermore, although numerous studies have 
suggested that arginase-1 expression is restricted to neutrophils in humans, recent studies 
have proposed the presence of arginase-1 macrophages in mycobacterial granulomas 
following clinical use of pegylated human recombinant arginase for cancer treatment in 
humans.  
 
4.7 Future directions 
 
The following questions would be addressed in prospective studies: 
1. To what extent our observation is relevant to HPV infection in humans? 
HPV16.E7 transgenic mouse reflects the biology of human squamous cancers 
associated with HPV oncoprotein induced-immune suppression, in which only E7 genes of 
the papillomavirus are expressed (13). However, this model does not reflect the complete 
immunobiology of HPV infection in humans. Indeed, previous studies have shown that not 
only E7 but also the E6 oncoprotein plays an important role in the local inflammatory 
responses and tumour specific immunity (42, 99, 207). Therefore, further studies will 
investigate the inflammatory response to DNCB in both the E6 and E7 and E6xE7 transgenic 
animals to dissect the role of these two oncoproteins in driving innate immunity to DNCB.  
 
2. Is E7-driven epidermal hyperplasia responsible for the enhanced recruitment of myeloid 
cells and induction of IL-17A and arginase-1 in response to DNCB application? 
Numerous studies have highlighted the crosstalk between hyperproliferative epithelium 
and innate immune cells (208, 209). We speculated that the activation of IL-17A and 
arginase-1 might be dependent on HPV16.E7 oncoprotein-induced epidermal hyperplasia. 
Therefore, it would be interesting to assess the effect of DNCB application on the recruitment 
of immune cells and production of arginase and IL-17A in RbmutxK14.E7 knock-in mice. These 
animals will allow us to compare the role for hyperplasia in DNCB-induced inflammation as 
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they express mutant retinoblastoma protein which is unable to be bound by E7 protein and 
thus remains functional for the control of the cell cycle and display normal skin without 
epidermal hyperplasia.  
3.  Whether arginase induction is driven by macrophage-derived IL-17A? 
The induction of both IL-17A and arginase-1 in DNCB-treated E7.Rag-/- skin observed 
in chapter 3 prompted us to speculate that macrophage-derived IL-17A is an important 
inducer of arginase-1. To address this hypothesis, the level of arginase-1/arginase activity will 
be examined in E7.Rag-/- skin following administration of IL-17A neutralizing antibody or 
matched-isotype control antibody.  
 
4. Why did DNCB-induced inflammation cause hyperinflammaton and shrinkage in K14.E7 
grafts but fail to induce complete graft rejection?  
The rejection of E7 skin graft is believed to be mediated by a strong cell-mediated 
immunity, particularly cytotoxic CD8+ T cells (210). The results shown in chapter 3 
demonstrated that DNCB application combined with E7 peptide immunization was unable to 
induce complete rejection of K14.E7 grafts in HPV16.E7-immunized recipient animals despite 
induction of hyperinflammation and significant shrinkage of the graft. This raised the question 
of whether the failure of rejection might be due to insufficient effector CD8+ T cells. First of all, 
the ability of DNCB treatment to enhance the recruitment or effector function of E7-specific 
CD8+ T cells in immunized recipient mice will be assessed by performing flow cytometric 
analysis of infiltrating graft lymphocytes. Furthermore, we wish to address whether 
combination therapy involving adoptive transfer of E7+ specific CD8+ T cells and DNCB 
application can enhance K14.E7 graft rejection. Alternatively, does DNCB-associated IL-17A 
and arginase not only play a proinflammatory role but also exert their immunosuppressive 
functions which might be responsible for the failure of K14.E7 graft rejection? Therefore, 
further studies will investigate the extent to which these molecules drive the function of 
effector CD8+ T cells. Collectively, dissecting these questions will enable us to understand the 
requirements that must be met to break the tolerance of HPV16.E7 oncoprotein.  
 
5. Whether a safer immune adjuvant such as aluminium hydroxide (alum) which also acts by 
activating inflammasome can be used as a suitable substitute for DNCB? 
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Alum has widely been used as a principle vaccine adjuvant for several clinical 
applications due to its ability to stimulate the innate immunity. Recent studies have reported 
that alum can activate the NLRP3 inflammasome, thereby inducing IL1β production and 
promoting innate cell infiltration (211, 212). Therefore, it will be interesting to investigate 
whether alum treatment can provoke hyperinflammatory response in HPV16 E7 transgenic 
mouse model as DNCB application. Nonetheless, it is also noted that alum is a poor inducer 
of cell-mediated immunity while DNCB application can activate both innate and cellular 
immunity. Therefore, aditional signals are required for particulates to effectively promote cell-
mediated immunity (213). Therefore, further studies will examine whether the combination of 
this adjuvant and E7-specific vaccine can induce the rejection of E7 expressing skin grafts.  
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Figure 4.1- The proposed mechanism of DNCB-induced hyperinflammation in 
HPV16.E7 expressing skin. 1) and 2) DNCB application to the skin results in induction of 
inflammasome-driven cytokines including IL-6 and IL-1β. 3) These molecules might be 
responsible for the induction of IL-17A, IL-4 and IL-10. 4) IL-17A promotes the recruitment of 
arginase-1 producing macrophages through induction of CCL2 and CCL7. 5); 6) and 7) 
Arginase-1 and IL-17A enhance neutrophil infiltration through inducing CXCL1 and and 
CXCL5 production, thereby mediating DNCB-induced hyperinflammation. Mo/Mac: 
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